{
    "id": "dbpedia_357_2",
    "rank": 50,
    "data": {
        "url": "https://patents.google.com/patent/KR20090052035A/en",
        "read_more_link": "",
        "language": "en",
        "title": "KR20090052035A - The co-culture method of sphingomonas sp. bacterial strain and aspergillus sp. fungus strain, new anti-cancer and antibiotic glionitrins derived from this co-culture method, and pharm",
        "top_image": "https://patentimages.storage.googleapis.com/44/5c/dc/2c2ca985b33026/112007083342887-PAT00003.png",
        "meta_img": "",
        "images": [
            "https://patentimages.storage.googleapis.com/9d/07/20/65543f4cc15a6b/112007083342887-PAT00011.png",
            "https://patentimages.storage.googleapis.com/fa/cd/b1/400435d2ed27eb/112007083342887-PAT00012.png",
            "https://patentimages.storage.googleapis.com/00/50/82/304d88ef8106e3/112007083342887-PAT00013.png",
            "https://patentimages.storage.googleapis.com/99/4d/94/80c2570dc1c8a7/112007083342887-PAT00015.png",
            "https://patentimages.storage.googleapis.com/1b/5f/dd/3fa2cb03b9fd1d/112007083342887-PAT00016.png",
            "https://patentimages.storage.googleapis.com/7e/cf/47/7547d737f9e657/112007083342887-PAT00017.png",
            "https://patentimages.storage.googleapis.com/0f/d3/41/7129c96b962208/112007083342887-PAT00001.png",
            "https://patentimages.storage.googleapis.com/0f/d3/41/7129c96b962208/112007083342887-PAT00001.png",
            "https://patentimages.storage.googleapis.com/a5/8d/1a/486ea230fb67c7/112007083342887-PAT00002.png",
            "https://patentimages.storage.googleapis.com/a5/8d/1a/486ea230fb67c7/112007083342887-PAT00002.png",
            "https://patentimages.storage.googleapis.com/44/5c/dc/2c2ca985b33026/112007083342887-PAT00003.png",
            "https://patentimages.storage.googleapis.com/44/5c/dc/2c2ca985b33026/112007083342887-PAT00003.png",
            "https://patentimages.storage.googleapis.com/77/e5/84/e9e3e1078de10d/112007083342887-PAT00004.png",
            "https://patentimages.storage.googleapis.com/77/e5/84/e9e3e1078de10d/112007083342887-PAT00004.png",
            "https://patentimages.storage.googleapis.com/7e/bd/a6/aa05eb1a449efd/112007083342887-PAT00005.png",
            "https://patentimages.storage.googleapis.com/7e/bd/a6/aa05eb1a449efd/112007083342887-PAT00005.png",
            "https://patentimages.storage.googleapis.com/d6/93/13/460ac05c6a508e/112007083342887-PAT00006.png",
            "https://patentimages.storage.googleapis.com/d6/93/13/460ac05c6a508e/112007083342887-PAT00006.png",
            "https://patentimages.storage.googleapis.com/88/4e/bb/82589958bef994/112007083342887-PAT00007.png",
            "https://patentimages.storage.googleapis.com/88/4e/bb/82589958bef994/112007083342887-PAT00007.png",
            "https://patentimages.storage.googleapis.com/62/b3/5f/0bf36946ba3ba3/112007083342887-PAT00008.png",
            "https://patentimages.storage.googleapis.com/62/b3/5f/0bf36946ba3ba3/112007083342887-PAT00008.png",
            "https://patentimages.storage.googleapis.com/ae/23/69/f72349411bb56a/112007083342887-PAT00009.png",
            "https://patentimages.storage.googleapis.com/ae/23/69/f72349411bb56a/112007083342887-PAT00009.png",
            "https://patentimages.storage.googleapis.com/c7/5b/85/38b6a3e49800e2/112007083342887-PAT00010.png",
            "https://patentimages.storage.googleapis.com/c7/5b/85/38b6a3e49800e2/112007083342887-PAT00010.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2007-11-20T00:00:00",
        "summary": "",
        "meta_description": "The present invention is a novel  Sphingomonas  bacterial strain KMK-001 cultured in a liquid medium, a novel  Aspegillus  strain KMC-901 cultured separately in a liquid medium in the culture medium of the bacterial strains Mixed culture of sphingomonas bacteria-aspergillus fungus, which is mixed culture by addition, novel glionitrins biosynthesized therefrom, and glynitrin or a pharmaceutically acceptable salt thereof as an active ingredient It relates to a pharmaceutical composition. The glinitrine has a strong cytotoxic effect on cancer cells, and can be usefully used as an anticancer agent or antibiotic by showing an antibiotic effect against 10 harmful bacteria including the new bacterial strain KMK-001 of sphingmonas.\n   \n     \n   \n    Sphingomonas Bacteria, Aspergillus Fungus, Sphingomonas Bacteria-Aspergillus Fungus Mixed Culture, Glionitrins, Anticancer, Antibiotic.",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://patents.google.com/patent/KR20090052035A/en",
        "text": "ì´í, ë³¸ ë°ëª ì ìì¸í ì¤ëª íë¤.Hereinafter, the present invention will be described in detail.\n\në³¸ ë°ëª ì ìíë²í¸ KCCM10888Pë¡ ê¸°íë ì¤íê³ ëª¨ëì¤ ì(Sphingomonas) ë°í ë¦¬ì ê· ì£¼ KMK-001ë¥¼ ì ê³µíë¤.The present invention provides the Sphingomonas bacterial strain KMK-001 deposited with accession number KCCM10888P.\n\në³¸ ë°ëª ìë¤ì ìê³¡ê´ì° ë´ë¶ìì ì°ì±ë(pH) 3.0ì ë¬¼ì ì±ì·¨í í ìì¬ë¶ë¦¬íì¬ ì¹¨ì ë¬¼ì ì»ìë¤. ìê¸° ì¹¨ì ë¬¼ì ìë¦¬ìì¼ìì íííì¬ í¬ìí í ë°°ì§ì ì ì¢ í í ë°°ìíë©´ì ë¨ì¼ ê· ì£¼ë¥¼ ë¶ë¦¬ ë° ì ë³íì¬ ì¡ì²´ ë°°ì§ì ì ì¢ í í ë¤ì ë°°ìíìë¤. íë³´ë ê· ì£¼ì ì¢ ë¶ìì ì¼ìì²´ DNAë¥¼ ë¶ë¦¬íì¬ íê¸°ì ê°ì 16S rDNA ì¼ê¸°ìì´ì ë¶ìíì¬ ê²°ì íìì¼ë©°, ê·¸ ê²°ê³¼ ê· ì£¼ KMK-001ì ì¤íê³ ëª¨ëì¤ ì(Sphingomonas sp. A1XXyl1-5)ê³¼ 98.0%ì ìëì±ì ë³´ììì íì¸í¨ì¼ë¡ì¨ ìê¸° KMK-001ì´ ì¤íê³ ëª¨ëì¤ ìì ìíë ì ê· ì¢ ìì ì ì ììë¤. KMK-001ì ì°¨íë ì¤ ë°°ì§ìì í©ì ì ì¡ì± ì½ë¡ëë¥¼ íì±íë©°, ìì¥ì ìí´ ì§ì°ì¼ê³¼ í©ì°ì¼ì íìì ì¼ë¡ ìêµ¬íë ê²ì íì¸í¨ì¼ë¡ì¨ ê·¸ë ìì± ê°ê· ìì ì ì ììë¤(ë 1 ë° ë 2 ì°¸ì¡°). ìê¸° ê· ì£¼ KMK-001ì íêµ­ ë¯¸ìë¬¼ ë³´ì¡´ ì¼í°ì 2007ë  11ì 7ì¼ìë¡ ê¸°ííìë¤(ìíë²í¸: KCCM10888P).The present inventors collected water of acidity (pH) 3.0 in the Limgok mine and centrifuged to obtain a precipitate. The precipitate was suspended and diluted in physiological saline, and then inoculated into the medium, followed by cultivation, to isolate and select a single strain, inoculate the liquid medium, and then incubate again. Species analysis of the obtained strain was determined by analyzing the 16S rDNA sequence by separating chromosomal DNA, and as a result, strain KMK-001 was 98.0% homologous to Sphingomonas sp. A1XXyl1-5. By confirming that the KMK-001 was found to be a novel species belonging to the sphingosmonas genus. KMK-001 formed yellow mucus colonies in Chapex dox medium, and it was confirmed that Gram-negative bacillus was confirmed by confirming that nitrates and sulfates were required for growth (see FIGS. 1 and 2). The strain KMK-001 was deposited on November 7, 2007 at the Korea Microbial Conservation Center (Accession Number: KCCM10888P).\n\në³¸ ë°ëª ì ì ê·í ê· ì£¼ KMK-001ì 16S rDNA ì¼ê¸°ìì´ì íê¸°ì ê°ë¤:16S rDNA nucleotide sequence of the novel strain KMK-001 of the present invention is as follows:\n\nAGAGTTTGAT CCTGGCTCAG AACGAACGCT GGCGGCATGC CTAATACATG CAAGTCGAAC GATCACTTCG GTGGTAGTGG CGCACGGGTG CGTAACGCGT GGGAATCTGC CCTTGGGTTC GGAATAACAG TTGGAAACGA CTGCTAATAC CGGATGATGA CGTAAGTCCA AAGATTTATC GCCCAAGGAT GAGCCCGCGT AGGATTAGCT AGTTGGTGAG GTAAAGGCTC ACCAAGGCAA CGATCCTTAG CTGGTCTGAG AGGATGATCA GCCACACTGG GACTGAGACA CGGCCCAGAC TCCTACGGGA GGCAGCAGTA GGGAATATTG GACAATGGGG GCAACCCTGA TCCAGCAATG CCGCGTGAGT GATGAAGGCC TTAGGGTTGT AAAGCTCTTT TACCCGAGAT GATAATGACA GTATCGGGAG AATAAGCTCC GGCTAACTCC GTGCCAGCAG CCGCGGTAAT ACGGAGGGAG CTAGCGTTGT TCGGAATTAC TGGGCGTAAA GCGCACGTAG GCGGCGATTT AAGTCAGAGG TGAAAGCCCG GGGCTCAACC CCGGAACTGC CTTTGAGACT GGATTGCTAG AATCTTGGAG AGGCGGGTGG AATTCCGAGT GTAGAGGTGA AATTCGTAGA TATTCGGAAG AACACCAGTG GCGAAGGCGG CCCGCTGGAC AAGTATTGAC GCTGAGGTGC GAAAGCGTGG GGAGCAAACA GGATTAGATA CCCTGGTAGT CCACGCCGTA AACGATGATA ACTAGCTGCC GGGGCACATG GTGTTTCGGT AGCGCAGCTA ACGCATTAAG TTATCCGCCT GGGGAGTACG GTCGCAAGAT TAAAACTCAA AGGAATTGAC GGGGGCCTGC ACAAGCGGTG GAGCATGTGG TTTAATTCGA AGCAACGCGC AGAACCTTAC CAACGTTTGA CATCCCTATC GCGGATCGTG GAGACACTTT CCTTCAGTTC GGCTGGATAG GTGACAGGTG CTGCATGGCT GTCGTCAGCT CGTGTCGTGA GATGTTGGGT TAAGTCCCGC AACGAGCGCA ACCCTCGCCT TTAGTTGCCA GCATTTAGTT GGGTACTCTA AAGGAACCGC CGGTGATAAG CCGGAGGAAG GTGGGGATGA CGTCAAGTCC TCATGGCCCT TACGCGTTGG GCTACACACG TGCTACAATG GCGACTACAG TGGGCAGCCA CTCCGCGAGG AGGAGCTAAT CTCCAAAAGT CGTCTCAGTT CGGATTGTTC TCTGCAACTC AAGAGCATGA AGGCGGAATC GCTAGTAATC GCGGATCAGC ATGCCGCGGT GAATACGTTC CCAGGCCTTG TACACACCGC CCGTCACACC ATGGGAGTTG GATTCACCTG AAGGCGCTGC GCTAACTCGC AAGAGAGGCA GGCGACCACG GTGGGTTTAG CGACTGGGGT GAAGTCGTAA CAAGGTAGCC GTAGGGGAAC CTGCGGCTGG ATCACCTCCT T(ìì´ë²í¸ 1)AGAGTTTGAT CCTGGCTCAG AACGAACGCT GGCGGCATGC CTAATACATG CAAGTCGAAC GATCACTTCG GTGGTAGTGG CGCACGGGTG CGTAACGCGT GGGAATCTGC CCTTGGGTTC GGAATAACAG TTGGAAACGA CTGCTAATAC CGGATGATGA CGTAAGTCCA AAGATTTATC GCCCAAGGAT GAGCCCGCGT AGGATTAGCT AGTTGGTGAG GTAAAGGCTC ACCAAGGCAA CGATCCTTAG CTGGTCTGAG AGGATGATCA GCCACACTGG GACTGAGACA CGGCCCAGAC TCCTACGGGA GGCAGCAGTA GGGAATATTG GACAATGGGG GCAACCCTGA TCCAGCAATG CCGCGTGAGT GATGAAGGCC TTAGGGTTGT AAAGCTCTTT TACCCGAGAT GATAATGACA GTATCGGGAG AATAAGCTCC GGCTAACTCC GTGCCAGCAG CCGCGGTAAT ACGGAGGGAG CTAGCGTTGT TCGGAATTAC TGGGCGTAAA GCGCACGTAG GCGGCGATTT AAGTCAGAGG TGAAAGCCCG GGGCTCAACC CCGGAACTGC CTTTGAGACT GGATTGCTAG AATCTTGGAG AGGCGGGTGG AATTCCGAGT GTAGAGGTGA AATTCGTAGA TATTCGGAAG AACACCAGTG GCGAAGGCGG CCCGCTGGAC AAGTATTGAC GCTGAGGTGC GAAAGCGTGG GGAGCAAACA GGATTAGATA CCCTGGTAGT CCACGCCGTA AACGATGATA ACTAGCTGCC GGGGCACATG GTGTTTCGGT AGCGCAGCTA ACGCATTAAG TTATCCGCCT GGGGAGTACG GTCGCAAGAT TAAAACTCAA AGGAATTGAC GGGGGCCTGC ACAAGCGGTG GAGCATGTGG TTTAATTCGA AGCAACGCGC AGAACCTTAC CAACGTTTGA CATCCCTATC GCGGATCGTG GAGACACTTT CCTTCAGTTC GGCTGGATAG GTGACAGGTG CTGCATGGCT GTCGTCAGCT CGTGTCGTGA GATGTTGGGT TAAGTCCCGC AACGAGCGCA ACCCTCGCCT TTAGTTGCCA GCATTTAGTT GGGTACTCTA AAGGAACCGC CGGTGATAAG CCGGAGGAAG GTGGGGATGA CGTCAAGTCC TCATGGCCCT TACGCGTTGG GCTACACACG TGCTACAATG GCGACTACAG TGGGCAGCCA CTCCGCGAGG AGGAGCTAAT CTCCAAAAGT CGTCTCAGTT CGGATTGTTC TCTGCAACTC AAGAGCATGA AGGCGGAATC GCTAGTAATC GCGGATCAGC ATGCCGCGGT GAATACGTTC CCAGGCCTTG TACACACCGC CCGTCACACC ATGGGAGTTG GATTCACCTG AAGGCGCTGC GCTAACTCGC AAGAGAGGCA GGCGACCACG GTGGGTTTAG CGACTGGGGT GAAGTCGTAA CAAGGTAGCC GTAGGGGAAC CTGCGGCTGG ATCACCTCCT T (SEQ ID NO: 1)\n\nëí, ë³¸ ë°ëª ì ìíë²í¸ KCCM10889Pë¡ ê¸°íë ìì¤í¼ì§ë¬ì¤ ì(Aspergillus) ê³°í¡ì´ ê· ì£¼ KMC-901ì ì ê³µíë¤. ìê¸° ê· ì£¼ KMC-901ì íêµ­ ë¯¸ìë¬¼ ë³´ì¡´ ì¼í°ì 2007ë  11ì 7ì¼ìë¡ ê¸°ííìë¤(ìíë²í¸: KCCM10889P).The present invention also provides Aspergillus fungus strain KMC-901 deposited with accession number KCCM10889P. The strain KMC-901 was deposited on November 7, 2007 in Korea microbial conservation center (accession number: KCCM10889P).\n\nìê¸° ê· ì£¼ KMC-901ì ê· ì§ë½ì ì´ê¸°ìë ë°±ìì ìí¸ëª¨ìì ëë©´ì ìê°ì´ ê°ìë¡ ì¤ìë¶ë¶ì ì²­ë¡ì ìì­ì´ ì§í´ì§ë©´ì ëì´ì§ë©° ë¤ì íìì ì¤ìë¶ë¶ì´ íì±ëì´, ìì¤í¼ì§ë¬ì¤ í¸ë¯¸ê°í¬ì¤(Aspergillus fumigatus) ê³°í¡ì´ì ê· ì§ë½ê³¼ ëì¼í ííë¥¼ ëìë¤(ë 3 ì°¸ì¡°)(ì ê°ì§, ë¯¸ìë¬¼ëê°, 3ê¶: 192-194, 2007). KMC-901ì ê· ì¬ì²´ë ê²©ë²½ì ê°ì§ê³ ììì¼ë©°, ìì¤í¼ì§ë¬ì¤(Aspergillus) ì ê³°í¡ì´ì í¹ì§ì ì¸ ë¶ììëë¥¼ ëíë´ìë¤(ë 4 ì°¸ì¡°)(ì ê°ì§, ë¯¸ìë¬¼ëê°, 3ê¶: 192-194, 2007). ëí, KMC-901ì ì°¨íë ì¤ ë°°ì§ìì ì¡ì²´ë°°ìíì¬ ìì°ëë ì´ì°¨ëì¬ì°ë¬¼ì ê³ ìì¡ì²´í¬ë¡ë§í ê·¸ëí¼-ì§ëë¶ìê¸°(HPLC-MS) ë° íµìê¸°ê³µëª ë¶ê´ê¸°(NMR)ì ì´ì©íì¬ ë¶ìí ê²°ê³¼, ìì¤í¼ì§ë¬ì¤ í¸ë¯¸ê°í¬ì¤(Aspergillus fumigatus)ì í¹ì§ì ì¸ ì±ë¶ì¸ ê¸ë¦¬ì¤í¡ì A(Gliotoxin) ë° ìë¡í´ A(Pseurotin A)ì ì¡´ì¬ê° íì¸ëì ë¤(Igarash, Y. et al. Journal of Antibiotic, 57: 748-754, 2004). ìê¸°í íííì  ë° ííì  í¹ì§ì íµíì¬ ê· ì£¼ KMC-901ì ìì¤í¼ì§ë¬ì¤ í¸ë¯¸ê°í¬ì¤(Aspergillus fumigatus)ì ìíë ê³°í¡ì´ë¡ì ê²°ì íìê³ , ìì¤í¼ì§ë¬ì¤ í¸ë¯¸ê°í¬ì¤(Aspergillus fumigatus) KMC-901ë¡ ëª ëª íìë¤.The fungal colonies of the strain KMC-901 initially have a white fleece shape, and as time goes on, the central turquoise area becomes darker and wider, and a gray central part is formed again, Aspergillus pumigatus ( Aspergillus). fumigatus ) showed the same morphology as fungal colonies (see FIG. 3) (Jeong-Jin Jung, Microbial Illustrated Book, Volume 3: 192-194, 2007). Mycelium of KMC-901 had a septum and showed characteristic conidia of the fungus of the genus Aspergillus (see FIG. 4) (Jeong-jin, Microbial Illustrated, Volume 3: 192-194, 2007). In addition, secondary metabolites produced by liquid culture of KMC-901 in the Chapedox medium were analyzed by high-performance liquid chromatography-mass spectrometry (HPLC-MS) and nuclear magnetic resonance spectroscopy (NMR). The presence of Gliotoxin A and Pseurotin A, a characteristic component of Aspergillus fumigatus , has been identified (Igarash, Y. et al. Journal of Antibiotic, 57: 748-754, 2004). Wherein the morphological and chemical characteristics throughout the KMC-901 strain was determined as a fungus belonging to Aspergillus fumigatus Fu (Aspergillus fumigatus), Aspergillus fumigatus Fu (Aspergillus fumigatus ) KMC-901.\n\nëí, ë³¸ ë°ëª ì ìê¸° ì¤íê³ ëª¨ëì¤ ì ì ê· ë°í ë¦¬ì ê· ì£¼ë¥¼ ì¡ì²´ ë°°ìí ë°°ìì¡ì ë³ëë¡ ì¡ì²´ ë°°ìë ìì¤íì§ë¬ì¤ ì(Aspegillus) ê³°í¡ì´ ê· ì£¼ ëë ê· ì£¼ë¥¼ í¬í¨í ë°°ìì¡ì ê°íì¬ ë°°ìíë ë¨ê³ë¥¼ í¬í¨íë ê· ë³µí©ì²´ì í¼í©ë°°ìë°©ë²ì ì ê³µíë¤.In addition, the present invention is a mixture of bacteria complex comprising the step of culturing by adding a culture medium containing the Aspegillus fungus strain or strain cultured separately liquid liquid culture medium cultured the sphingomonas sp . Provide a culture method.\n\nìê¸° í¼í©ë°°ìë°©ë²ì ì¤íê³ ëª¨ëì¤ ì ì ê· ë°í ë¦¬ì ê· ì£¼ ë° ìì¤íì§ë¬ì¤ ì(Aspegillus) ê³°í¡ì´ ê· ì£¼ë¥¼ 1000 : 1.0 ~ 1000 : 0.1ì ë¹ì¨ë¡ í¼í©íë ê²ì´ ë°ëì§íê³ , 1000 : 0.5ì ë¹ì¨ë¡ í¼í©íë ê²ì´ ëì± ë°ëì§íë ì´ì íì ëì§ ìëë¤.In the mixed culture method, it is preferable to mix sphingomonas novel bacterial strains and Aspegillus fungi strains in a ratio of 1000: 1.0 to 1000: 0.1, more preferably in a ratio of 1000: 0.5. Preferred but not limited to this.\n\në³¸ ë°ëª ìë¤ì ì ê· ë°í ë¦¬ì ê· ì£¼ KMK-001ê³¼ ê³°í¡ì´ ê· ì£¼ KMC-901ì ê°ê° ì¡ì²´ ë°°ì§ì ì ì¢ í í ë°°ìíìë¤. ì¤íê³ ëª¨ëì¤ ì ê· ì£¼ KMK-001ì ë°°ìì¡ 1ë¦¬í°ì ê³°í¡ì´ ê· ì£¼ KMC-901ì í¬í¨í ë°°ìì¡ 500 ë§ì´í¬ë¡ë¦¬í°ë¥¼ ê°íì¬ í¼í©ë°°ìíìì¼ë©°, ê³ ìì¡ì²´ í¬ë¡ë§í ê·¸ëí¼ë¥¼ ì´ì©íì¬ í¼í©ë°°ìì¡ì ë¶ìíì¬ ìë¡ì´ íí©ë¬¼ì ìì° ì¬ë¶ë¥¼ íì¸íìë¤. ë°í ë¦¬ì ê· ì£¼ KMK-001 ë° ê³°í¡ì´ ê· ì£¼ KMC-901ì ê°ê° 15ì¼ ëì ë¨ì¼ ë°°ìí ë°°ìì¡ì ë¶ìê²°ê³¼, ê¸ë¦¬ì¤ëí¸ë¦°ë¤ì ì í ì¡´ì¬íì§ ììì¼ë KMK-001ê³¼ KMC-901ì 15ì¼ ëì í¼í© ë°°ìí ë°°ìì¡ì ë¨¸ë¬´ë¦ ìê° 18.072ë¶ì í¼í¬ìì ê¸ë¦¬ì¤ëí¸ë¦° Aì, 18.767ë¶ì í¼í¬ìì ê¸ë¦¬ì¤ëí¸ë¦° Bë¥¼ ëíë´ìë¤. KMK-001ê³¼ KMC-901ì í¼í©ë°°ìì¼ 2ì¼ì§¸ë¶í° ê²©ì¼ë¡ í¼í©ë°°ìì¡ì ë¶ìí ê²°ê³¼, ê¸ë¦¬ì¤ëí¸ë¦°ë¤ì í¼í©ë°°ì 8ì¼ì§¸ë¶í° ìì°ëê¸° ììíìë¤.The inventors cultured the new bacterial strain KMK-001 and the fungal strain KMC-901, respectively, after inoculating them in a liquid medium. 500 microliters of the culture medium containing the fungus strain KMC-901 was added to 1 liter of the culture medium of sphingomonas strain KMK-001, and the mixed culture was analyzed using high-performance liquid chromatography to confirm the production of new compounds. . As a result of analysis of the culture medium in which the bacterial strain KMK-001 and the fungal strain KMC-901 were monocultured for 15 days, glynitrin was not present at all, but the culture solution containing the mixed culture of KMK-001 and KMC-901 for 15 days remained. Glynitrin A was shown at the peak of 18.072 minutes and glynitrin B was shown at the peak of 18.767 minutes. As a result of analyzing the mixed culture solution every other day from the 2nd day of the mixed culture of KMK-001 and KMC-901, the glynitrins were produced from the 8th day of the mixed culture.\n\nëí, ë³¸ ë°ëª ì ìê¸° í¼í©ë°°ìë°©ë²ì¼ë¡ ë°°ìë ê· ë³µí©ì²´ì ë°°ìì¡ì ì ê³µíë¤.In addition, the present invention provides a culture solution of the bacterial complex cultured by the mixed culture method.\n\nëí, ë³¸ ë°ëª ì ìê¸° í¼í©ë°°ìë°©ë²ì¼ë¡ ë°°ìë ê· ë³µí©ì²´ì ë°°ìì¡ì¼ë¡ë¶í° ë¶ë¦¬ëë íê¸° ííì 1 ëë ííì 2ë¡ íìëë íí©ë¬¼ì ì ê³µíë¤.In addition, the present invention provides a compound represented by the following formula (1) or (2) separated from the culture solution of the culture complex cultured by the mixed culture method.\n\nìê¸° íí©ë¬¼ì ì ê·í íí©ë¬¼ë¡ì ë³¸ ë°ëª ìì ìíì¬ ê¸ë¦¬ì¤ëí¸ë¦°(Glionitrins)ì¼ë¡ ëª ëª ëìë¤.The compound was named by the inventor as glionitrins as a novel compound.\n\nnì í©ì ê°ìë¡ì 1 ë´ì§ 4ì´ë¤.n is 1 to 4 as the number of sulfur.\n\nXë ìì, ëë C1 ë´ì§ C5ìí¬ê¸°ì´ë©°, ìë¡ ê°ê±°ë ë¤ë¥¼ ì ìì¼ë©° ëª¨ë ë¹ëì¹­íìììì ì´ì±ì§ì²´ë¥¼ í¬í¨íë¤. X is hydrogen, or C 1 To C 5 alkyl groups, which may be the same or different from one another and include isomers in all asymmetric carbons.\n\në³¸ ë°ëª ì ìê¸° ê¸ë¦¬ì¤ëí¸ë¦°(Glionitrins) íí©ë¬¼ì íê¸°ì ë¨ê³ë¤ì í¬í¨íë ë°©ë²ì ìí´ ì ì¡°ëë¤.The glionitrins compound of the present invention is prepared by a method comprising the following steps.\n\n1) ì¤íê³ ëª¨ëì¤ ì ê· ì£¼ KMK-001ì ë°°ìì¡ 1ë¦¬í°ì 500 ë§ì´í¬ë¡ë¦¬í°ì ê³°í¡ì´ ê· ì£¼ KMC-901ì í¬í¨í ë°°ìì¡ì ê°íì¬ í¼í©ë°°ìí í ë°°ìì¡ì ì ê¸°ì©ë§¤ë¥¼ ê°íì¬ ì¶ì¶íë ë¨ê³;1) adding a culture medium containing 500 microliter of the fungal strain KMC-901 to 1 liter of the culture medium of sphingomonas strain KMK-001, mixed culture, followed by extracting by adding an organic solvent to the culture medium;\n\n2) ë¨ê³ 1)ì ì¶ì¶ë¬¼ì ê°ì ê±´ì¡°í í ì»¬ë¼ í¬ë¡ë§í ê·¸ëí¼ë¥¼ ì´ì©íì¬ ë¶íë¬¼ì ìëíë ë¨ê³; ë°2) drying the extract of step 1) under reduced pressure to obtain a fraction using column chromatography; And\n\n3) ë¨ê³ 2)ì ë¶íë¬¼ë¡ë¶í° ì¶ê°ë¡ ì»¬ë¼ í¬ë¡ë§í ê·¸ëí¼ë¥¼ ì´ì©íì¬ íí©ë¬¼ ì ë¶ë¦¬ì ì íë ë¨ê³,3) separating and purifying the compound further from column fractions using column chromatography,\n\nìê¸° ì ì¡°ë°©ë²ì ìì´ì, ë¨ê³ 1)ì í¼í©ë°°ìì 10ì¼ ~ 20ì¼ ëì ë°°ìíë ê²ì´ ë°ëì§íê³ , 12ì¼ ~ 18ì¼ ëì ë°°ìíë ê²ì´ ëì± ë°ëì§íë ì´ì íì ëì§ ìëë¤. ìê¸° ì ê¸°ì©ë§¤ë ì´ì°ìí¸, ë¶íì¬, ì¼íë©í¸ë  ëë í´ë¡ë¡í¬ë¦ì ì¬ì©íë ê²ì´ ë°ëì§íë ì´ì íì ëì§ ìëë¤. ìê¸° ì¶ì¶ì ì´ìê³ì¶ì¶, ê³ ìì¶ì¶ ëë ì´ìíì¶ì¶ë² ë±ì ì¶ì¶ì¥ì¹ë¥¼ ì´ì©í ë°©ë², ëë XAD ë° HP-20ë¥¼ í¬í¨í í¡ì°©ìì§ë¥¼ ì´ì©íë ë°©ë²ì¼ë¡ ëì²´ ê°ë¥íë ì´ì íì ëì§ ìëë¤. ì¶ì¶ì ì©ë§¤ë¥¼ í¼í©ë°°ìì¡ ë¶ëì 1 ë´ì§ 3ë°° ì²¨ê°íì¬ ì¶ì¶íë ê²ì´ ë°ëì§íë©°, 2ë°° ì²¨ê°íì¬ ì¶ì¶íë ê²ì´ ëì± ë°ëì§íë¤. ìì¨ìì ì¶ì¶íë ê²ì´ ë°ëì§íë ì´ì íì íë ê²ì ìëë¤. ìì¸ë¬ ì¶ì¶ íìë 1 ë´ì§ 5íì¸ ê²ì´ ë°ëì§íë©°, 3í ë°ë³µ ì¶ì¶íë ê²ì´ ëì± ë°ëì§íë ì´ì íì ëë ê²ì ìëë¤.Â Â Â Â Â Â In the above production method, the mixed culture of step 1) is preferably cultured for 10 days to 20 days, more preferably 12 to 18 days, but is not limited thereto. The organic solvent is preferably ethyl acetate, butanol, methylene chloride or chloroform, but is not limited thereto. The extraction may be replaced by a method using an extraction apparatus such as supercritical extraction, high pressure extraction or ultrasonic extraction, or a method using an adsorption resin including XAD and HP-20, but is not limited thereto. At the time of extraction, the solvent is preferably extracted by adding 1 to 3 times the amount of the mixed culture solution, and more preferably by adding twice the solvent. Extraction at room temperature is preferred, but is not limited thereto. In addition, the number of extraction is preferably 1 to 5 times, more preferably three times repeated extraction is not limited thereto.\n\nìê¸° ì ì¡°ë°©ë²ì ìì´ì, ë¨ê³ 2)ì ê°ìê±´ì¡°ë íì ì§ê³µëì¶ê¸°(Rotary Vacuum Evaporator)ë¥¼ ì¬ì©íë ê²ì´ ë°ëì§íë ì´ì íì ëì§ ìëë¤. ìê¸° ê°ìê±´ì¡° ì ì¨ëë 20 ~ 40âì¸ ê²ì´ ë°ëì§íê³ 30âì¸ ê²ì´ ëì± ë°ëì§íë ì´ì íì ëì§ ìëë¤. In the manufacturing method, the vacuum drying of step 2) is preferably a rotary vacuum evaporator, but is not limited thereto. When drying under reduced pressure, the temperature is preferably 20 to 40 Â° C, more preferably 30 Â° C, but is not limited thereto.\n\nìê¸° ì ì¡°ë°©ë²ì ìì´ì, ë¨ê³ 2) ëë ë¨ê³ 3)ì ì»¬ë¼ í¬ë¡ë§í ê·¸ëí¼ë ì¤ë¦¬ì¹´ê², ì¸íë±ì¤, RP-18, í´ë¦¬ìë¯¸ë, ëìí(Toyopearl) ë° XAD ìì§ë¡ ì´ë£¨ì´ì§ ê·¸ë£¹ì¼ë¡ë¶í° ì íë ì¶©ì§ì ë¥¼ ì´ì©í ì»¬ë¼ì ì´ì©í ì»¬ë¼ í¬ë¡ë§í ê·¸ëí¼ë¥¼ ìííì¬ íì±íí©ë¬¼ì ë¶ë¦¬ ë° ì ì í ì ìë¤. ì»¬ë¼ í¬ë¡ë§í ê·¸ëí¼ë íìì ë°ë¼ ì ì í ì¶©ì§ì ë¥¼ ì ííì¬ ìì°¨ë¡ ì¤ìí ì ìì¼ë©°, ì©ë§¤ë¡ í´ë¡ë¡í¬ë¦(CHCl3)-ë©íì¬, ìí¸ ìì¸í ì´í¸(ethyl acetate)-ë©íì¬, ëí´ë¡ë¡ë©í(dicloromethane)-ë©íì¬, ë©íì¬-ë¬¼ ëë ìì¸í ëí¸ë¦´-ë¬¼ì ì´ì©í ì ìì¼ë ì´ì íì ëì§ ìëë¤. In the above method, the column chromatography of step 2) or step 3) is a column using a column using a filler selected from the group consisting of silica gel, Sephadex, RP-18, polyamide, Toyopearl and XAD resin. Chromatography can be performed to isolate and purify the active compound. Column chromatography can be carried out several times by selecting the appropriate filler as required. The solvent can be chloroform (CHCl 3 ) -methanol, ethyl acetate-methanol, dichloromethane-methanol, methanol-water or Acetonitrile-water may be used but is not limited thereto.\n\në³¸ ë°ëª ìë¤ì ìê¸° ì´ì°ìí¸ ì¶ì¶ì¡ì ê°ì ê±´ì¡°íì¬ ì»ì ì¶ì¶ë¬¼ì ì­ì ì»¬ë¼ í¬ë¡ë§í ê·¸ëí¼ë¥¼ ì´ì©íì¬ ì¬ì¯ ê°ì ë¶íì¼ë¡ ëëìë¤. ì©ë¦¬ ì¡°ê±´ì ë¬¼ê³¼ ìì¸í ëí¸ë¦´ì ì¬ì©íìì¼ë©° 20% ìì¸í ëí¸ë¦´/ë¬¼ë¡ ììíì¬ 20%ì© ìì¸í ëí¸ë¦´ì í¨ëì ì¦ê°ìì¼°ì¼ë©°, 100% ë©íì¬ì ìµì¢ ì ì¶ì©ë§¤ë¡ ì¬ì©íìë¤. ì´ë¡ë¶í° ì»ì´ì§ ë¶íë¬¼ì ê³ ìì¡ì²´í¬ë¡ë§í ê·¸ëí¼ë²ì ì´ì©íì¬ ì£¼ì±ë¶ì ë¶ìí ê²°ê³¼ 60% ìì¸í ëí¸ë¦´/ë¬¼ ë¶íë¬¼ìì ì ê·í ê¸ë¦¬ì¤ëí¸ë¦°ì íì¸ëìë¤. ìê¸° ë¶íë¬¼ì ì¶ê°ì ì¼ë¡ ì´ì°ìí¸ ë° ì¼íë©í¸ë ì ì©ë§¤ë¡ ì¬ì©íì¬ 90% ì¼íë©í¸ë /ì´ì°ìí¸ ë° 60% ì¼íë©í¸ë /ì´ì°ìí¸ì ë±ì©ë§¤ ì©ë¦¬ì¡°ê±´ì ê°ì§ê³ ìì ì¡ì²´ í¬ë¡ë§í ê·¸ëí¼ë²ì íµí´ ì ì íìì¼ë©° ë¨¸ë¬´ë¦ ìê° 10ë¶ì íê¸° ííì 3ì¼ë¡ íìëë ê¸ë¦¬ì¤ëí¸ë¦° Aì ë¨¸ë¬´ë¦ ìê° 15ë¶ì ííì 4ë¡ íìëë ê¸ë¦¬ì¤ëí¸ë¦° Bë¥¼ ê°ê° ìëíìë¤. The present inventors divided the extract obtained by drying the ethyl acetate extract under reduced pressure into six fractions using reverse phase column chromatography. Elution conditions were water and acetonitrile, starting with 20% acetonitrile / water to increase the content of acetonitrile by 20%, and 100% methanol was used as the final solvent. The resulting fractions were analyzed for the main components using high performance liquid chromatography, and new glynitrin was identified in the 60% acetonitrile / water fraction. In addition to the above fractions, ethyl acetate and methylene chloride were used as a solvent, and the mixture was purified by normal phase liquid chromatography using isocratic elution conditions of 90% methylene chloride / ethyl acetate and 60% methylene chloride / ethyl acetate. Glynitrin A represented by the following formula (3) and glynitrin B represented by the formula (4) were obtained at the retention time of 15 minutes, respectively.\n\nìê¸° ë¶ë¦¬í íí©ë¬¼ë¤ì MS ë° íµë¶ê´ê¸°ë¥¼ ì´ì©íì¬ ë¶ìíì¬ ííêµ¬ì¡°ë¥¼ ê·ëª íìì¼ë©°, ê¸ë¦¬ì¤ëí¸ë¦° Aë ë¶ìë 353ì´ë©° ë¶ììì´ C13H11N3O5S2ì¸ ë¬´ì í ì°í©ì ë¶ë§ìì´ê³ , ê¸ë¦¬ì¤ëí¸ë¦° Bë ë¶ìë 383ì´ë©° ë¶ììì´ C15H17N3O5S2ì¸ ë¬´ìì ì ì¡ì± ë°ê³ í ë¬¼ì§ì¸ ê²ì íì¸íìë¤. ëí, ìê¸° ê¸ë¦¬ì¤ëí¸ë¦° Aë¥¼ ë¬¼, ìì¸í ë í¸ë¦´ ìì©ì¡, ë©íì¬ ìì©ì¡ ëë DMSO ì©ì¡ ììì ì¤ì¨ì ë°©ì¹í ë ì¼í©íë¬¼(ê¸ë¦¬ì¤ëí¸ë¦° C) ë° ì¬í©íë¬¼(ê¸ë¦¬ì¤ëí¸ë¦° D)ì´ ìì±ëìê³ ì´ë¤ì ííêµ¬ì¡°ë¥¼ ê·ëª íìë¤. The separated compounds were analyzed by MS and nuclear spectroscopy to determine the chemical structure. The glynitrin A was an amorphous light yellow powder having a molecular weight of 353 and a molecular formula of C 13 H 11 N 3 O 5 S 2 , and glynitrin B was found to be a colorless, viscous semisolid substance having a molecular weight of 383 and a molecular formula of C 15 H 17 N 3 O 5 S 2 . In addition, when the glynitrin A was left at room temperature in water, acetonitrile aqueous solution, methanol aqueous solution or DMSO solution, trisulfide (glionitrin C) and tetrasulfide (glionitrin D) were formed and their chemical structure Was identified.\n\nëí, ë³¸ ë°ëª ì ìê¸° í¼í©ë°°ìë°©ë²ì¼ë¡ ë°°ìë ê· ë³µí©ì²´ì ë°°ìì¡ ëë ê¸ë¦¬ì¤ëí¸ë¦°ì í¨ì íë í­ìì ë¥¼ ì ê³µíë¤.The present invention also provides an anticancer agent containing a culture solution or glynitrin of a culture complex cultured by the mixed culture method.\n\nìê¸° ìì ìì, ê°ì, ëì¥ì, íì ëë ì ë¦½ì ìì¸ ê²ì í¹ì§ì¼ë¡ íë¤.The cancer is characterized in that the stomach cancer, liver cancer, colon cancer, lung cancer or prostate cancer.\n\nìê¸° ê¸ë¦¬ì¤ëí¸ë¦°ì ìì¸í¬ë ì±ì American Type Culture Collection(ATCC, Manassas, VA, USA)ë¡ë¶í° ë¶ìë°ì AGS(ìì, ATCC ì¸í¬ì½ë- CRL-1739TM), HepG2(ê°ì, HB-8065TM), HCT116 (ëì¥ì, CCL-247TM), A549(íì, CCL-185TM) ë° DU145(ì ë¦½ì ì, HTB-81TM) ìì¸í¬ì£¼ë¥¼ ì¬ì©íì¬ íê°íìë¤.The cancer cytotoxicity of the glinitrine is AGS (stomach cancer, ATCC cell code- CRL-1739 TM ), HepG2 (liver cancer, HB-8065 TM ), HCT116 (prepared from the American Type Culture Collection (ATCC, Manassas, VA, USA)) Colorectal cancer, CCL-247 â¢ ), A549 (lung cancer, CCL-185 â¢ ) and DU145 (prostate cancer, HTB-81 â¢ ) cancer cell lines were evaluated.\n\në³¸ ë°ëª ìë¤ì ê¸ë¦¬ì¤ëí¸ë¦°ì ìì¸í¬ì ëí ì¸í¬ë ì±í¨ê³¼ë¥¼ ììë³´ê¸° ìí´, ìíê´ ë´ìì MTT(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltrazdium bromide) ë¶ìë²ì ì´ì©íì¬ ì´ììë ìì¸í¬ ìì ì¸¡ì íë ë°©ë²ì ìííìë¤. ìê¸° ê²°ê³¼, ê¸ë¦¬ì¤ëí¸ë¦°ì ìì(AGS), ê°ì(HepG2), ëì¥ì(HCT-116), íì(A549) ë° ì ë¦½ì ì(DU-145)ì ê°ë ¥í í­ìí¨ê³¼ê° ìë ê²ì íì¸íìë¤. ë°ë¼ì, ë³¸ ë°ëª ì ìê¸° ê· ë³µí©ì²´ì ë°°ìì¡ ëë ê¸ë¦¬ì¤ëí¸ë¦°ì í­ìì ë¡ ì´ì©ë ì ììì ì ì ìë¤.In order to determine the cytotoxic effect of glynitrin on cancer cells, the present inventors have used live cancer cells using MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphenyltrazdium bromide) assay in vitro. The method of measuring the amount was carried out. As a result, it was confirmed that glynitrin has a strong anticancer effect on gastric cancer (AGS), liver cancer (HepG2), colon cancer (HCT-116), lung cancer (A549) and prostate cancer (DU-145). Therefore, it can be seen that the culture solution of the complex or glynitrin of the present invention can be used as an anticancer agent.\n\nìì¸ë¬, ë³¸ ë°ëª ì ìê¸° í¼í©ë°°ìë°©ë²ì¼ë¡ ë°°ìë ê· ë³µí©ì²´ì ë°°ìì¡ ëë ê¸ë¦¬ì¤ëí¸ë¦°ì í¨ì íë í­ê· ì ë¥¼ ì ê³µíë¤.In addition, the present invention provides an antimicrobial agent containing a culture solution or glynitrin of a culture complex cultured by the mixed culture method.\n\nìê¸° í­ê· ì ë ì¤íê³ ëª¨ëì¤ ì(Sphingomonas) ë°í ë¦¬ì ê· ì£¼ì ëí í­ê· í¨ê³¼ê° ìë ê²ì í¹ì§ì¼ë¡ íë¤.The antimicrobial agent is characterized in that it has an antimicrobial effect against Sphingomonas bacteria strains.\n\në³¸ ë°ëª ìë¤ì ê¸ë¦¬ì¤ëí¸ë¦°ì í­ê· í¨ê³¼ë¥¼ ììë³´ê¸° ìí´, ëì¤í¬ íì° ì¤íì íµí´ì ê¸ë¦¬ì¤ëí¸ë¦°ì ë°í ë¦¬ì ê· ì£¼ì ëí í­ê· í¨ê³¼ë¥¼ íì¸íìë¤. ìê¸° ê· ì£¼ë¥¼ ëë§í íì² ë°°ì§ì ìíêµ°ì¸ ê¸ë¦¬ì¤ëí¸ë¦°ê³¼ ìì±ëì¡°êµ°ì¸ ì°í¼ì¤ë¦°ì ê°ê° í¡ììí¨ ëì¤í¬ë¥¼ ë°°ìí í ê´ì°°íìë¤. ìê¸° ê²°ê³¼, ê¸ë¦¬ì¤ëí¸ë¦°ì í¡ììí¨ ëì¤í¬ìì ë°í ë¦¬ìë í©ìì ëê³ ê¸ë¦¬ì¤ëí¸ë¦°ì ìí´ ë°í ë¦¬ìê° ìì¥íì§ ëª»íë ìì­ì´ ëì¤í¬ ì£¼ë³ì ë¬´ì ìíì¼ë¡ ëíë¬ì¼ë©°, ëì¡°êµ°ì¼ë¡ ì¬ì©í ì°í¼ì¤ë¦°ê³¼ ì ì¬í í­ê· í¨ê³¼ë¥¼ ëíëì íì¸íìë¤. The present inventors confirmed the antimicrobial effect of the bacterial strain of glinotrin through a disk diffusion experiment in order to determine the antimicrobial effect of the glynitrin. The strains were observed after culturing the discs in which the test group glynitrin and the positive control ampicillin were respectively absorbed in the agar medium. As a result, the bacterium was yellow in the glynitrin-absorbed disc, and the area where the bacteria could not grow by the glynitrin appeared as a colorless circle around the disc, and showed an antibacterial effect similar to the ampicillin used as a control. Confirmed.\n\në³¸ ë°ëª ìë¤ì ê¸ë¦¬ì¤ëí¸ë¦° Aì Bì í­ê· í¨ê³¼ë¥¼ ììë³´ê¸° ìí´, American Type Culture Collection(ATCC, Manassas, VA, USA)ë¡ë¶í° ë¶ìë°ì ë§ì´í¬ë¡ì½ì¿ ì¤ ë¡ì´í ì°ì¤(Micrococcus leuteus) IFC 12708, ë°ì¤ë¬ì¤ ìë¸í¸ë¬ì¤(Bacillus subtilis) ATCC 6633, íë¡í ì°ì¤ ë¶ê°ë¦¬ì¤(Proteus vulgaris) ATCC 3851, ì´ëª¨ë¬ë¼ í°í¼ë¬´ë¦¬ì(Salmonella typhimurium) ATCC 1 4028 ë° 3ì¢ ì ë©í°ì¤ë¦° ë´ì± í©ìí¬ëìêµ¬ê· (MRSA)ì¸ ì¤íí¼ë¡ì½ì¿ ì¤ ìì°ë ì°ì¤(Staphylococcus aureus) ATCC 43300, ì¤íí¼ë¡ì½ì¿ ì¤ ìì°ë ì°ì¤(S. aureus) ATCC 700787 ë° ì¤íí¼ë¡ì½ì¿ ì¤ ìì°ë ì°ì¤(S. aureus) ATCC 700788ì ëíì¬ íê°íìë¤. ìê¸° ê²°ê³¼, ê¸ë¦¬ì¤ëí¸ë¦° Bë ëª¨ë ìíêµ°ìì í­ê· ìì©ì´ ìë ë°ë©´ì, ê¸ë¦¬ì¤ëí¸ë¦° Aë 4ì¢ ì ë¹ë´ì±ê· ì ì ìì±ëì¡°êµ°ì¼ë¡ ì¬ì©í ìí¼ì¤ë¦°(Ampicillin)ê³¼ ì ì¬í ê°ë ¥í í­ê· ìì©ì ëíë´ìë¤. í¹í, ê¸ë¦¬ì¤ëí¸ë¦° Aë 3ì¢ ì MRSA ê· ë¤ìë ìì±ëì¡°êµ°ì¼ë¡ ì¬ì©í ìí¼ì¤ë¦°(Ampicillin)ì í­ê· ìì©ë³´ë¤ 15ë°° ì´ìì ê°ë ¥í ë©í°ì¤ë¦° ë´ì± í©ì í¬ëìêµ¬ê· ì ëí í­ê· ìì©ì ëíë´ìë¤. ëí, ìì¤í¼ì§ë¬ì¤ í¸ë¯¸ê°í¬ì¤(Aspergillus fumigatus) HIC 6094ì T.ë£¨ë¸ë¼(Trichophyton rubrum) IFO 9185ì ëí ê¸ë¦¬ì¤ëí¸ë¦° Aì Bì í­ì§ê· ìì©ì íê°í ê²°ê³¼, ìê¸° í­ê· ìì©ê³¼ ì ì¬íê² ê¸ë¦¬ì¤ëí¸ë¦° Bë í­ì§ê· í¨ê³¼ê° ìë ë°ë©´, ê¸ë¦¬ì¤ëí¸ë¦° Aë í­ì§ê· í¨ê³¼ë¥¼ ëíë´ìë¤. The inventors of the present invention, Micrococcus ( Micrococcus ) received from the American Type Culture Collection (ATCC, Manassas, VA, USA) to investigate the antimicrobial effect of glynitrin A and B leuteus) IFC 12708, Bacillus sub-blocks bus (Bacillus subtilis) ATCC 6633, Proteus vulgaris (Proteus vulgaris) ATCC 3851, Salmonella typhimurium bunch moth (Salmonella typhimurium) ATCC 1 4028 and the methicillin-resistant Staphylococcus aureus (MRSA) star fatigue of the three nose kusu aureus (Staphylococcus aureus ) ATCC 43300, Staphylococcus aureus ( S. aureus ) It was evaluated against ATCC 700787, and co-stars fatigue Syracuse aureus (S. aureus) ATCC 700788. As a result, glynitrin B had no antimicrobial activity in all test groups, while glynitrin A showed a strong antimicrobial activity similar to Ampicillin used as a positive control in four non-resistant bacteria. In particular, glynitrin A showed an antimicrobial activity against methicillin-resistant Staphylococcus aureus more than 15 times stronger than that of Ampicillin, which was used as a positive control for three MRSA bacteria. In addition, Aspergillus fumigatus Fu (Aspergillus fumigatus ) HIC 6094 and T. lubrum ( Trichophyton rubrum ) As a result of evaluating the antifungal action of glynitrin A and B on IFO 9185, glynitrin B had no antifungal effect, while glynitrin A showed an antifungal effect similarly to the above antibacterial action.\n\në°ë¼ì, ë³¸ ë°ëª ì ìê¸° ê· ë³µí©ì²´ì ë°°ìì¡ ëë ê¸ë¦¬ì¤ëí¸ë¦°ì í­ê· ì ë¡ ì´ì©ë ì ììì ì ì ìë¤(í 3 ë° ë 6 ì°¸ì¡°).Therefore, it can be seen that the culture solution or glynitrin of the complex of the present invention can be used as an antibacterial agent (see Table 3 and FIG. 6).\n\në³¸ ë°ëª ì í­ìì  ëë í­ê· ì ë ííì 1 ëë ííì 2ë¡ íìëë íí©ë¬¼ì ì½íì ì¼ë¡ íì©ê°ë¥í ì¼ì í¬í¨í ì ìë¤. ìê¸° ì½íì ì¼ë¡ íì©ê°ë¥í ì¼ì ì ë¦¬ì°(free acid)ì ìí´ íì±ë ë¶ê°ì¼ì´ ì ì©íë¤. ì í©í ì ë¦¬ì°ì¼ë¡ë ì ê¸°ì°ê³¼ ë¬´ê¸°ì°ì ì¬ì©í ì ìì¼ë©°, ë¬´ê¸°ì°ì¼ë¡ë ì¼ì°, ë¸ë¡¬ì°, í©ì° ë° ì¸ì° ë±ì ì¬ì©í ì ìê³ ì ê¸°ì°ì¼ë¡ë êµ¬ì°ì°(citric acid), ì´ì°, ì ì°, ì£¼ìì°(tartariac acid), ë§ë ì¸ì°, í¸ë§ë¥´ì°(fumaric acid), í¬ë¦ì°, íë¡í¼ì¨ì°(propionic acid), ì¥ì´ì°, í¸ë¦¬íë£¨ì¤ë¡ìì¸í¸ì°, ë²¤ì¡°ì°, ê¸ë£¨ì½ì°, ë©íì í°ì°, ê¸ë¦¬ì½ì°, ìì ì°, 4-í¨ë£¨ìì í°ì°, ê°ë£©í¬ë¡ ì°, ì ë³¸ì°, ê¸ë£¨íì° ëë ìì¤íë¥´í¸ì° ë±ì ì¬ì©í ì ìë¤. ëìê°, ì½íì ì¼ë¡ íì©ê°ë¥í ì¼ë¿ë§ ìëë¼, íµìì ë°©ë²ì ìí´ ì¡°ì ë ì ìë ëª¨ë ì¼, ìíë¬¼ ë° ì©ë§¤íë¬¼ì ëª¨ë í¬í¨í ì ìë¤.The anticancer or antimicrobial agent of the present invention may include a pharmaceutically acceptable salt in the compound represented by Formula 1 or Formula 2. The pharmaceutically acceptable salts are useful addition salts formed with free acid. Suitable free acids may be organic and inorganic acids, inorganic acids may be hydrochloric acid, bromic acid, sulfuric acid and phosphoric acid, and organic acids may be citric acid, acetic acid, lactic acid, tartariac acid, maleic acid, Fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, galluxuronic acid, embonic acid, glutamic acid or aspartic acid Etc. can be used. Furthermore, not only pharmaceutically acceptable salts, but also all salts, hydrates and solvates that can be prepared by conventional methods may be included.\n\në³¸ ë°ëª ì í­ìì  ëë í­ê· ì ë ííì 1 ëë ííì 2ë¡ íìëë íí©ë¬¼ ì¤ìì íë ì´ìì ì íì ì¼ë¡ í¨ì í ì ìì¼ë©°, ìê¸° ì±ë¶ì ì¶ê°ë¡ ëì¼ ëë ì ì¬í ê¸°ë¥ì ëíë´ë ì í¨ì±ë¶ì 1ì¢ ì´ì í¨ì í ì ìë¤.Â Â Â Â Â The anticancer agent or antimicrobial agent of the present invention may optionally contain one or more of the compounds represented by Formula 1 or Formula 2, and may further contain one or more active ingredients exhibiting the same or similar functions in addition to the above components.\n\në³¸ ë°ëª ì í­ìì  ëë í­ê· ì ë ìì í¬ì¬ ìì ê²½êµ¬ ëë ë¹ê²½êµ¬ë¡ í¬ì¬ê° ê°ë¥íë©° ì¼ë°ì ì¸ ìì½í ì ì ì ííë¡ ì¬ì©ë ì ìë¤. ì¦, ë³¸ ë°ëª ì í­ìì  ëë í­ê· ì ë ì¤ì  ìì í¬ì¬ ìì ê²½êµ¬ ë° ë¹ê²½êµ¬ì ì¬ë¬ ê°ì§ ì íì¼ë¡ í¬ì¬ë ì ìëë°, ì ì íí ê²½ì°ìë ë³´íµ ì¬ì©íë ì¶©ì§ì , ì¦ëì , ê²°í©ì , ìµì¤ì , ë¶í´ì  ë° ê³ë©´íì±ì  ë±ì í¬ìì  ëë ë¶íì ë¥¼ ì¬ì©íì¬ ì¡°ì ëë¤. ê²½êµ¬ í¬ì¬ë¥¼ ìí ê³ í ì ì ìë ì ì , íì , ì°ì , ê³¼ë¦½ì  ë° ìº¡ìì  ë±ì´ í¬í¨ëë©°, ì´ë¬í ê³ í ì ì ë ë³¸ ë°ëª ì ì½íì  ì¡°ì±ë¬¼ì ì ì´ë íë ì´ìì ë¶íì  ìë¥¼ ë¤ë©´, ì ë¶, íì°ì¹¼ì, ìí¬ë¡ì¤, ë½í ì¤ì¤ ë° ì ¤ë¼í´ ë±ì ìì´ ì¡°ì ëë¤. ëí ë¨ìí ë¶íì  ì´ì¸ì ë§ê·¸ë¤ì, ì¤í°ë ì´í¸, íí¬ ê°ì ì¤íì ë¤ë ì¬ì©ëë¤. ê²½êµ¬ í¬ì¬ë¥¼ ìí ì¡ì ì ì ë¡ë ííì , ë´ì©ì¡ì , ì ì  ë° ìë½ì  ë±ì´ í´ë¹ëëë° íí ì¬ì©ëë ë¨ì í¬ìì ì¸ ë¬¼, ë¦¬í´ë íë¼í ì´ì¸ì ì¬ë¬ ê°ì§ ë¶íì , ìë¥¼ ë¤ë©´ ìµì¤ì , ê°ë¯¸ì , ë°©í¥ì  ë° ë³´ì¡´ì  ë±ì´ í¬í¨ë ì ìë¤. ë¹ê²½êµ¬ í¬ì¬ë¥¼ ìí ì ì ìë ë©¸ê· ë ìì©ì¡, ë¹ìì±ì©ì , ííì , ì ì , ëê²°ê±´ì¡°ì ì  ë° ì¢ì ê° í¬í¨ëë¤. ë¹ìì±ì©ì ì ííì©ì ë¡ë íë¡íë ê¸ë¦¬ì½, í´ë¦¬ìí¸ë  ê¸ë¦¬ì½, ì¬ë¦¬ë¸ ì¤ì¼ê³¼ ê°ì ìë¬¼ì± ê¸°ë¦, ìí¸ì¬ë ì´í¸ì ê°ì ì£¼ì¬ ê°ë¥í ìì¤í ë¥´ ë±ì´ ì¬ì©ë ì ìë¤. ì¢ì ì ê¸°ì ë¡ë ìí ì(witepsol), ë§í¬ë¡ê³¨, í¸ì(tween) 61, ì¹´ì¹´ì¤ì§, ë¼ì°ë¦°ì§, ê¸ë¦¬ì¸ë¡¤ ë° ì ¤ë¼í´ ë±ì´ ì¬ì©ë ì ìë¤. ë³¸ ë°ëª ì í­ìì  ëë í­ê· ì ë ë¹ê²½êµ¬ í¬ì¬ì í¼íì£¼ì¬, ì ë§¥ì£¼ì¬ ëë ê·¼ì¡ë´ ì£¼ì¬ë¥¼ íµí ì ìë¤.Â Â Â Â Â Anticancer or antimicrobial agents of the present invention can be administered orally or parenterally during clinical administration and can be used in the form of general pharmaceutical formulations. That is, the anticancer or antimicrobial agent of the present invention may be administered in various oral and parenteral dosage forms during actual clinical administration, and when formulated, diluents such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants that are commonly used Or using excipients. Solid preparations for oral administration include tablets, pills, powders, granules and capsules, and the like, which may be used in the pharmaceutical composition of the present invention at least one excipient such as starch, calcium carbonate, sucrose, lactose And gelatin etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium, styrate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups, and may include various excipients such as wetting agents, sweeteners, fragrances and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol and gelatin may be used. The anticancer or antimicrobial agent of the present invention may be via subcutaneous injection, intravenous injection or intramuscular injection during parenteral administration.\n\në³¸ ë°ëª ì í­ìì  ëë í­ê· ì ì ë°ëì§í í¬ì¬ëì íìì ìí ë° ì²´ì¤, ì§ë³ì ì ë, ì½ë¬¼íí, í¬ì¬ê²½ë¡ ë° ê¸°ê°ì ë°ë¼ ë¤ë¥´ì§ë§, ë¹ì ìì ìí´ ì ì íê² ì íë ì ìë¤. Preferred dosages of the anticancer or antimicrobial agents of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.\n\nì´í, ë³¸ ë°ëª ì íê¸° ì¤ìì ë° ì ì ìì ìíì¬ ìì¸í ì¤ëª íë¤.Hereinafter, the present invention will be described in detail by the following examples and formulation examples.\n\në¨, íê¸° ì¤ìì ë° ì ì ìë ë³¸ ë°ëª ì êµ¬ì²´ì ì¼ë¡ ììíë ê²ì´ë©°, ë³¸ ë°ëª ì ë´ì©ì´ íê¸°ì ì¤ìì ë° ì ì ìì ìí´ íì ëë ê²ì ìëë¤. However, the following Examples and Preparation Examples specifically illustrate the present invention, and the contents of the present invention are not limited by the following Examples and Preparation Examples.\n\n<< ì¤ììExample 1> í¼í©ë°°ìì ì ì©ë ë°í ë¦¬ì ë° ê³°í¡ì´ ê· ì£¼ íì ë° ì ë³Â 1> Screening and screening bacteria and fungi strains for mixed culture\n\në³¸ ë°ëª ìë¤ì ê°ìë ê°ë¦ì ìê³¡ë©´ ìê³¡ê´ì° ë´ë¶ìì ì°ì±ë(pH) 3.0ì ë¬¼ì ì±ì·¨í í ìì¬ë¶ë¦¬íì¬ ì¹¨ì ë¬¼ì ì»ìë¤. ìê¸° ì¹¨ì ë¬¼ì ìë¦¬ìì¼ìì íííì¬ í¬ìí í ìì´ì íì²ë°°ì§(YMA)ì ì°¨íë ì¤ íì²ë°°ì§(CDA)ì ì ì¢ í í 25âìì 10ì¼ê° ë°°ìíë©´ì ë¨ì¼ ê· ì£¼ë¥¼ ë¶ë¦¬íì¬ 300ì¬ê°ì ê· ì£¼ë¥¼ íë³´íìë¤. ì´ ì¤ í¼í©ë°°ìì ì¬ì©í ì¸ê· ê³¼ ê³°í¡ì´ ê· ì£¼ë¤ì ê°ê° ì ííì¬ ì°¨íë ì¤ ì¡ì²´ ë°°ì§ì ì ì¢ í í 25â ì§í ë°°ìê¸°ìì 5 ~ 7ì¼ê° ë°°ìíìë¤. íë³´ë ê· ì£¼ì ì¢ ë¶ìì ì¼ìì²´ DNAë¥¼ ë¶ë¦¬íì¬ 16S rDNA ì¼ê¸°ìì´ì ë¶ìíì¬ ê²°ì íìì¼ë©°, ê·¸ ê²°ê³¼ ê· ì£¼ KMK-001ì ì¤íê³ ëª¨ëì¤ ì(Sphingomonas sp. A1XXyl1-5)ê³¼ 98.0%ì ìëì±ì ë³´ìë¤. ì´ë KMK-001ì´ ì¤íê³ ëª¨ëì¤ ìì ìíë ì ê· ì¢ ìì ì ì ìë¤. KMK-001ì ì°¨íë ì¤ ë°°ì§(30 g Saccharose, 3 g Sodium Nitrate, 1 g Dipotassium Phosphate, 0.5 g Magnesium Sulfate, 0.5 g Potassium Chloride, 0.01 g, Ferrous Sulfate in 1L of DI water )ìì í©ì ì ì¡ì± ì½ë¡ëë¥¼ íì±íë©°, ìì¥ì ìí´ ì§ì°ì¼ê³¼ í©ì°ì¼ì íìì ì¼ë¡ ìêµ¬íë ê·¸ë ìì± ê°ê· ìì íì¸íìë¤(ë 1 ë° ë 2 ì°¸ì¡°). ìê¸° ê· ì£¼ KMK-001ë íêµ­ ë¯¸ìë¬¼ ë³´ì¡´ ì¼í°ì 2007ë  11ì 7ì¼ìë¡ ê¸°ííìë¤(ìíë²í¸: KCCM10888P).The present inventors collected water of acidity (pH) 3.0 in Imgok-myeon, Imgok-myeon, Gangneung-si, Gangwon-do, and centrifuged to obtain a precipitate. The precipitate was suspended in physiological saline, diluted, and then inoculated in YM agar medium (YMA) and Chapex dos agar medium (CDA), followed by incubation at 25 Â° C. for 10 days to obtain 300 strains by separating a single strain. Among them, bacteria and fungi strains to be used for the mixed culture were selected and inoculated in the Chapex dox liquid medium, and then cultured in a 25 Â° C. shaking incubator for 5 to 7 days. Species analysis of the obtained strain was determined by analyzing the 16S rDNA sequence by separating the chromosomal DNA. As a result, strain KMK-001 showed 98.0% homology with Sphingomonas sp. A1XXyl1-5. It can be seen that KMK-001 is a new species belonging to the genus Sphingomonas. KMK-001 forms yellow mucus colonies in Chapex dox medium (30 g Saccharose, 3 g Sodium Nitrate, 1 g Dipotassium Phosphate, 0.5 g Magnesium Sulfate, 0.5 g Potassium Chloride, 0.01 g, Ferrous Sulfate in 1 L of DI water) In addition, it was confirmed that the Gram-negative bacillus which requires nitrates and sulfates for growth (see FIGS. 1 and 2). The strain KMK-001 was deposited on November 7, 2007 at the Korea Microbial Conservation Center (Accession Number: KCCM10888P).\n\nëí, ë³¸ ë°ëª ìë¤ì ê°ìë íë°±ì ì¥ì±íê´ ìì§ê°±ë 150ë¯¸í° ì§íì ê³ ì¸ ë¬¼ê³¼ ìíì ííì¡ì ì±ì·¨í í, ìì¬ë¶ë¦¬íì¬ ì¹¨ì ë¬¼ì ì»ìë¤. ìê¸° ì¹¨ì ë¬¼ì ë©¸ê· ì ì ìì íííì¬ í¬ìí í ì°¨íë ì¤ íì²ë°°ì§(CDA)ì ì ì¢ í í 25âìì 14ì¼ê° ë°°ìíë©´ì ë¨ì¼ ê³°í¡ì´ ê· ì£¼ë¥¼ ë¶ë¦¬íì¬ ê³°í¡ì´ ê· ì£¼ KMC-901ì íë³´íìë¤. ë¨ì¼ ê· ì£¼ë¡ ë¶ë¦¬ë KMC-901ë¥¼ ë¤ì ì°¨íë ì¤ íì²ë°°ì§(CDA)ìì ë°°ìíì¬ ìì¥íí ë° ìì ê´ì°°íìê³ , ê· ì¬ì²´, ê· ì¬ì ê²©ë²½, ë¶ììë³ ë° ìë­ì ê´ì°°íì¬ ì¢ ì ëì íìë¤. ëí, ê· ì£¼ KMC-901ì´ ìì°íë ì±ë¶ì ííì  ë¶ì ê²°ê³¼ë¥¼ ì¢ ëì ì ìí ìë£ë¡ ì¬ì©íìë¤. ê· ì£¼ KMC-901ì ê· ì§ë½ì ì´ê¸°ìë ë°±ìì ìí¸ëª¨ìì ëë©´ì ìê°ì´ ê°ìë¡ ì¤ìë¶ë¶ì ì²­ë¡ì ìì­ì´ ì§í´ì§ë©´ì ëì´ì§ë©° ë¤ì íìì ì¤ìë¶ë¶ì´ íì±ëì´, ìì¤í¼ì§ë¬ì¤ í¸ë¯¸ê°í¬ì¤(Aspergillus fumigatus) ê³°í¡ì´ì ê· ì§ë½ê³¼ ëì¼í ííë¥¼ ëìë¤(ë 3 ì°¸ì¡°). KMC-901ì ê· ì¬ì²´ë ê²©ë²½ì ê°ì§ê³ ììì¼ë©°, ìì¤í¼ì§ë¬ì¤(Aspergillus) ì ê³°í¡ì´ì í¹ì§ì ì¸ ë¶ììëë¥¼ ëíë´ìë¤(ë 4 ì°¸ì¡°). ëí, KMC-901ì ì°¨íë ì¤ ë°°ì§ìì ì¡ì²´ë°°ìíì¬ ìì°ëë ì´ì°¨ëì¬ì°ë¬¼ì ê³ ìì¡ì²´í¬ë¡ë§í ê·¸ëí¼-ì§ëë¶ìê¸°(HPLC-MS) ë° íµìê¸°ê³µëª ë¶ê´ê¸°(NMR)ì ì´ì©íì¬ ë¶ìí ê²°ê³¼, ìì¤í¼ì§ë¬ì¤ í¸ë¯¸ê°í¬ì¤(Aspergillus fumigatus)ì í¹ì§ì ì¸ ì±ë¶ì¸ ê¸ë¦¬ì¤í¡ì A(Gliotoxin) ë° ìë¡í´ A(Pseurotin A)ì ì¡´ì¬ê° íì¸ëìë¤. ë°ë¼ì, ìê¸° íííì  ë° ííì  í¹ì§ì íµíì¬ ê· ì£¼ KMC-901ì ìì¤í¼ì§ë¬ì¤ í¸ë¯¸ê°í¬ì¤(Aspergillus fumigatus)ì ìíë ê³°í¡ì´ë¡ ê²°ì íìê³ , ìì¤í¼ì§ë¬ì¤ í¸ë¯¸ê°í¬ì¤(Aspergillus fumigatus) KMC-901ë¡ ëª ëª íìë¤. ìê¸° ê· ì£¼ KMC-009ë ê°ê° íêµ­ ë¯¸ìë¬¼ ë³´ì¡´ ì¼í°ì 2007ë  11ì 7ì¼ìë¡ ê¸°ííìë¤(ìíë²í¸: KCCM10889P).In addition, the present inventors collected a suspension of water and coal collected in a 150 meter underground tunnel of Jangseong Coal Mine in Taebaek, Gangwon-do, and centrifuged to obtain a precipitate. The precipitate was suspended in sterile purified water, diluted, inoculated in Chapex dox agar medium (CDA), and cultured at 25 Â° C. for 14 days to isolate a single fungal strain to secure fungal strain KMC-901. KMC-901 isolated as a single strain was cultured again in Chapex dox agar medium (CDA) to observe the growth type and color, and the species were identified by observing mycelia, mycelial septum, conidia disease and vesicles. In addition, the results of chemical analysis of the components produced by strain KMC-901 were used as data for species identification. The fungal colonies of strain KMC-901 initially had a white fleece shape, and as time went on, the central turquoise area became darker and wider, again forming a gray central part. Aspergillus pumigatus ( Aspergillus) fumigatus ) showed the same shape as the fungal colony of the fungus (see FIG. 3). Mycelium of KMC-901 had a septum and showed characteristic conidia of the genus Aspergillus (see FIG. 4). In addition, secondary metabolites produced by liquid culture of KMC-901 in the Chapedox medium were analyzed by high-performance liquid chromatography-mass spectrometry (HPLC-MS) and nuclear magnetic resonance spectroscopy (NMR). The presence of Gliotoxin A and Pseurotin A, a characteristic component of Aspergillus fumigatus , has been identified. Therefore, the morphological and chemical properties through the strain KMC-901 is Aspergillus Fu Micah was determined by fungi belonging to the tooth (Aspergillus fumigatus), Aspergillus fumigatus Fu (Aspergillus fumigatus ) KMC-901. The strain KMC-009 was each deposited on November 7, 2007 at the Korea Microbial Conservation Center (Accession Number: KCCM10889P).\n\n<< ì¤ììExample 2> Â 2> ì¤íê³ ëª¨ëì¤Sphingomonas ì(Â genus( SphingomonasSphingomonas ) ì ê· ê· ì£¼ New strain KMKKMK -001ê³¼ With -001 ìì¤íì§ë¬ì¤Aspergillus ì(Â genus( AspegillusAspegillus ) ê· ì£¼ Strain KMCKMC -901ì í¼í©ë°°ì-901 Mixed Cultures\n\në³¸ ë°ëª ìë¤ì ì ê· ë°í ë¦¬ì ê· ì£¼ KMK-001ê³¼ ê³°í¡ì´ ê· ì£¼ KMC-901ì ê°ê° ì°¨íë ì¤ ì¡ì²´ ë°°ì§ì ì ì¢ í í 25â ì§í ë°°ìê¸°ìì 3ì¼ê° ë°°ìëìë¤. ë ê°ì ê· ì£¼ë ëëë°°ìì ìí´ì 1ë¦¬í° ì¼ê°íë¼ì¤í¬ìì 0.5 ë¦¬í°ì ì°¨íë ì¤ ì¡ì²´ ë°°ì§ì ë°°ìëìê³ 2ì¼ì´ ì§ë í ì¤íê³ ëª¨ëì¤ ì ê· ì£¼ KMK-001ì ë°°ìì¡ì ê³°í¡ì´ ê· ì£¼ KMC-901ì 250 ë§ì´í¬ë¡ë¦¬í°ë¥¼ ê°í í í¼í©ë°°ì íìë¤. ê· ì£¼ë¤ì í¬í¨í í¼í©ë°°ìì¡ì íë¯¸ê²½ì¼ë¡ ê´ì°°íì¬ ë 5ììì ê°ì´ ê³°í¡ì´ì ê· ì¬ì²´ ì£¼ë³ì ìì ë°í ë¦¬ì ê· ì£¼ë¤ì´ í¨ê» ì¡´ì¬í¨ì ì§ìì ì¼ë¡ íì¸íìë¤(ë 5 ì°¸ì¡°). We inoculated the new bacterial strain KMK-001 and the fungal strain KMC-901 in Chapex dox liquid medium, respectively, and were incubated in a 25 Â° C. shaking incubator for 3 days. Two strains were incubated in 0.5 liter of Chapex dox liquid medium in a 1 liter Erlenmeyer flask for mass cultivation, and after 2 days 250 microliters of fungal strain KMC-901 was added to the culture medium of the sphincomonas strain KMK-001. Then mixed culture. The mixed culture solution containing the strains was observed under a microscope to continuously check the presence of small bacterial strains around the mycelia of the fungus as shown in FIG. 5 (see FIG. 5).\n\nëí, ì§ìì ì¼ë¡ ê³ ìì¡ì²´ í¬ë¡ë§í ê·¸ëí¼ë²ì ì¬ì©íì¬ í¼í©ë°°ìì¡ì¼ë¡ë¶í° ìë¡ì´ íí©ë¬¼ì ìì° ì¬ë¶ë¥¼ ë¶ìíìë¤. ë¶ìì¡°ê±´[ê¸°ê¸°: Agilent 1100 LC/MS system; ì©ì¶ìë: 0.7 mL/min; ì©ì¶ì¡: 10% ìì¸í ëí¸ë¦´/ë¬¼ë¡ë¶í° 100% ìì¸í ëí¸ë¦´ê¹ì§ 30ë¶ ëì ìì¸í ëí¸ë¦´ì ì¡°ì±ì ì¦ê°ìí´; ì»¬ë¼: Phenomenex Luna 5u C18(2) 4.6 x 150 mm; ê²ì¶ê¸°: DAD ìì¸ì ê²ì¶ê¸°(254 nm)]ì ê³ ìì¡ì²´ í¬ë¡ë§í ê·¸ëí¼ì ë¶ìê²°ê³¼, ë 7ìì ë³´ë ë°ì ê°ì´ ë°í ë¦¬ì ê· ì£¼ KMK-001 ë° ê³°í¡ì´ ê· ì£¼ KMC-901ì ê°ê° 15ì¼ ëì ë¨ì¼ ë°°ìí ë°°ìì¡ììë ê¸ë¦¬ì¤ëí¸ë¦°ë¤ì ì í ì¡´ì¬íì§ ììì§ë§ KMK-001 ë° KMC-901ì 15ì¼ ëì í¼í© ë°°ìí ë°°ìì¡ììë ë¨¸ë¬´ë¦ ìê° 18.072ë¶ì í¼í¬ì¸ ê¸ë¦¬ì¤ëí¸ë¦° Aì 18.767ë¶ì í¼í¬ì¸ ê¸ë¦¬ì¤ëí¸ë¦° Bë¥¼ ëíë´ìë¤. KMK-001 ë° KMC-901ì í¼í©ë°°ìì¼ 2ì¼ì§¸ë¶í° ê²©ì¼ë¡ í¼í©ë°°ìì¡ì ë¶ìí ê²°ê³¼, ê¸ë¦¬ì¤ëí¸ë¦°ë¤ì í¼í©ë°°ì 8ì¼ì§¸ë¶í° ìì°ëê¸° ììíìë¤.In addition, continuous high-speed liquid chromatography was used to analyze the production of new compounds from the mixed culture. Analytical conditions [instrument: Agilent 1100 LC / MS system; Elution rate: 0.7 mL / min; Eluent: increasing the composition of acetonitrile for 30 minutes from 10% acetonitrile / water to 100% acetonitrile; Column: Phenomenex Luna 5u C18 (2) 4.6 Ã 150 mm; Detector: DAD UV detector (254 nm)] As a result of the analysis of high-performance liquid chromatography, as shown in FIG. 7, glynitrin was obtained from the culture medium in which the bacterial strain KMK-001 and the fungal strain KMC-901 were cultured for 15 days each. Although not present at all, the culture medium in which KMK-001 and KMC-901 were mixed and cultured for 15 days showed glynitrin A, a peak of 18.072 minutes, and glynitrin B, a peak of 18.767 minutes. As a result of analyzing the mixed culture solution every other day from the 2nd day of the mixed culture of KMK-001 and KMC-901, glynitrins began to be produced from the 8th day of the mixed culture.\n\n<< ì¤ììExample 3> Â 3> ê¸ë¦¬ì¤ëí¸ë¦°ìGlynitrin ë¶ë¦¬ ì ì  ë°©ë²Â Separation Purification Method\n\në³¸ ë°ëª ìë¤ì ìê¸° <ì¤ìì 2>ìì íëí ë°°ìì¡ì ì´ì°ìí¸ì ì´ì©íì¬ ë°°ìì¡ìì ì ê¸°íí©ë¬¼ë¤ì ì¶ì¶íìë¤. ì¶ì¶ì¡ì íì ì§ê³µëì¶ê¸° (Rotary Vacuum Evaporator)ë¥¼ ì¬ì©íì¬ 30âìì ê°ìê±´ì¡°íì¬ ì»ì ì¶ì¶ë¬¼ì ì­ì ì»¬ë¼ í¬ë¡ë§í ê·¸ëí¼ë¥¼ ì´ì©íì¬ ì¬ì¯ ê°ì ë¶íì¼ë¡ ëëìë¤. ì©ë¦¬ ì¡°ê±´ì ë¬¼ê³¼ ìì¸í ëí¸ë¦´ì ì¬ì©íìì¼ë©° 20% ìì¸í ëí¸ë¦´/ë¬¼ë¡ ììíì¬ 20%ì© ìì¸í ëí¸ë¦´ì í¨ëì ì¦ê°ìì¼°ì¼ë©°, 100% ë©íì¬ì ìµì¢ ì ì¶ì©ë§¤ë¡ ì¬ì©íìë¤. ìê¸° ê³ ìì¡ì²´í¬ë¡ë§í ê·¸ëí¼ë²ì ì¬ì©íì¬ ì´ë¡ë¶í° ì»ì´ì§ ë¶íë¬¼ì ì£¼ì±ë¶ì ë¶ìí ê²°ê³¼ 60% ìì¸í ëí¸ë¦´/ë¬¼ ë¶íë¬¼ìì í¼í©ë°°ìì íµí´ ìë¡ì´ ìì°ë ì ê· ë¬¼ì§ ê¸ë¦¬ì¤ëí¸ë¦°ì ì¡´ì¬ê° íì¸ëìë¤. ìê¸° ë¶íë¬¼ì ì´ì°ìí¸ê³¼ ì¼íë©í¸ë ì ì©ë§¤ë¡ ì¬ì©íì¬ 90% ì¼íë©í¸ë /ì´ì°ìí¸ ë° 60% ì¼íë©í¸ë /ì´ì°ìí¸ì ë±ì©ë§¤ ì©ë¦¬ì¡°ê±´ì ê°ì§ê³ ìì ì¡ì²´ í¬ë¡ë§í ê·¸ëí¼ë²ì íµí´ ì ì íì¬ ë¨¸ë¬´ë¦ ìê° 10ë¶ì ê¸ë¦¬ì¤ëí¸ë¦° Aì ë¨¸ë¬´ë¦ ìê° 15ë¶ì ê¸ë¦¬ì¤ëí¸ë¦° Bë¥¼ ì»ìë¤. The present inventors extracted the organic compounds from the culture solution using ethyl acetate in the culture solution obtained in Example 2. The extract was dried under reduced pressure at 30 Â° C. using a rotary vacuum evaporator, and the extract was divided into six fractions using reverse phase column chromatography. Elution conditions were water and acetonitrile, starting with 20% acetonitrile / water to increase the content of acetonitrile by 20%, and 100% methanol was used as the final solvent. Analysis of the main components of the fractions obtained from the above by using the high performance liquid chromatography method confirmed the presence of the newly produced new substance glynitrin through mixed culture in a 60% acetonitrile / water fraction. The fractions were purified by normal phase liquid chromatography using ethyl acetate and methylene chloride as solvents with 90% methylene chloride / ethyl acetate and 60% methylene chloride / ethyl acetate with isocratic elution conditions. Glionitrile B was obtained 15 minutes of retention time with Lionitrin A.\n\n<< ì¤ììExample 4> Â 4> ê¸ë¦¬ì¤ëí¸ë¦°ìGlynitrin ê¸°ê¸°ë¶ìÂ Instrument analysis\n\në³¸ ë°ëª ìë¤ì ê¸°ê¸°ë¶ìì ì´ì©íì¬ ê¸ë¦¬ì¤ëí¸ë¦° Aì ê¸ë¦¬ì¤ëí¸ë¦° Bë¥¼ ííìì ê²°ì íìë¤. ë¶ë¦¬ë ê¸ë¦¬ì¤ëí¸ë¦° Aë¥¼ ë¬¼ ëë DMSO ì©ì¡ ììì ì¤ì¨ì ë°©ì¹í ë ì¼í©íë¬¼(ê¸ë¦¬ì¤ëí¸ë¦° C)ê³¼ ì¬í©íë¬¼(ê¸ë¦¬ì¤ëí¸ë¦° D)ì´ ìì±ëìê³ ì´ë¤ì ííêµ¬ì¡°ë¥¼ íê¸°ì ê°ì MS ìë£ ë° íµìê¸°ë¶ê´ê¸° ìë£ë¥¼ ë¶ìíì¬ ê·ëª íìë¤. ìê¸° ììì íì íµìê¸°ë¶ê´ê¸° ì¤íí¸ë¼ì ê°ê° 500MHzì 125MHzìì ì¸¡ì ëìì¼ë©°, ê¸ë¦¬ì¤ëí¸ë¦° Aë í´ë¡ë¡í¬ë¦-d ì©ë§¤ìì ì¸¡ì ëìê³ ê¸ë¦¬ì¤ëí¸ë¦° Bë ë©íì¬-d 4 ì©ë§¤ìì ì¸¡ì ëìë¤. The inventors determined the formula of glionotrin A and glionitrin B using instrumental analysis. When the isolated glynitrin A was left at room temperature in water or DMSO solution, trisulfide (glionitrin C) and tetrasulfide (glionitrin D) were produced and their chemical structures were as follows. Spectroscopic data were analyzed and identified. The hydrogen and carbon nuclear magnetic spectrometer spectra were measured at 500 MHz and 125 MHz, respectively, glynitrin A was measured in chloroform- d solvent and glynitrin B was measured in methanol- d 4 solvent.\n\nê¸ë¦¬ì¤ëí¸ë¦°Glionnitrin Aì Bì êµ¬ì¡°ì ëí Â For the structure of A and B 1One Hì H and 1313 C C NMRNMR ì ííì  Chemical ì´ëê°Moving value ê¸ë¦¬ì¤ëí¸ë¦° AGlionitrine A ê¸ë¦¬ì¤ëí¸ë¦° BGlionitrine B ìì¹location Î´H Î´ H Mult (J Hz)Mult (J Hz) Î´cÎ´c ìì¹location Î´H Î´ H Mult (J Hz)Mult (J Hz) Î´cÎ´c 1One 165.5165.5 CC 1One 166. 1166. 1 CC 2-NMe2-NMe 3.303.30 ss 27.827.8 CH3 CH 3 2-NMe2-NMe 3.203.20 ss 28.128.1 CH3 CH 3 3-SMe3-SMe 2.362.36 ss 12.212.2 CH3 CH 3 33 76.776.7 CC 33 72.472.4 CC 3aA3aA 4.344.34 dd(12.5, 10.0)dd (12.5, 10.0) 60.960.9 CH2 CH 2 3aA3aA 4.394.39 d(12.0)d (12.0) 63.963.9 CH2 CH 2 3aB3aB 4.524.52 dd(12.5, 6.0)dd (12.5, 6.0) 3aB3aB 3.983.98 d(12.0)d (12.0) 3a-OH3a-OH 3.423.42 dd(10.0, 6.0)dd (10.0, 6.0) 3a-OH3a-OH 44 161.4161.4 CC 44 163.0163.0 CC 5-N5-N 5-N5-N 5a5a 139.2139.2 CC 5a5a 141.9141.9 CC 66 8.758.75 d(2.5)d (2.5) 111.4111.4 CHCH 66 8.838.83 d (2.5)d (2.5) 112.2112.2 CHCH 77 148.9148.9 CC 77 148.0148.0 CC 88 8.148.14 br dd(8.5, 2.5)br dd (8.5, 2.5) 121.7121.7 CHCH 88 8.148.14 br dd(8.5, 2.5)br dd (8.5, 2.5) 121.2121.2 CHCH 99 7.537.53 br d(8.5)br d (8.5) 126.0126.0 CHCH 99 7.627.62 br d(8.5)br d (8.5) 125.9125.9 CHCH 9a9a 135.3135.3 CC 9a9a 137.3137.3 CC 10A10A 3.443.44 d(19.0)d (19.0) 36.836.8 CH2 CH 2 10A10A 3.733.73 br sbr s 39.239.2 CH2 CH 2 10B10B 4.404.40 br dd(19.0, 1.0)br dd (19.0, 1.0) 10B10B 10a-SMe10a-SMe 2.272.27 ss 13.213.2 CH3 CH 3 10a10a 74.474.4 CC 10a10a 71.871.8 CC\n\n<ê¸ë¦¬ì¤ëí¸ë¦° C><Glionitrine C>\n\nESI-MS: m/z 386 [M+H]+; ESI-MS: m / z 386 [M + H] + ;\n\n1H NMR(500 MHz, CDCl3): 3.40 (3H, s), 3.46(1H, dd, J=19.0, 1.0 Hz), 4.29(1H, dd, J=19, 1.0 Hz), 4.42(1H, br d, J=12.5 Hz), 4.80(1H, br d, J=12.5 Hz), 7.44(1H, br d, J=8.5 Hz), 8.10(1H, dd, J=8.5, 2.0 Hz), 8.89(1H, d, J=2.0Hz). 1 H NMR (500 MHz, CDCl 3 ): 3.40 (3H, s), 3.46 (1H, dd, J = 19.0, 1.0 Hz), 4.29 (1H, dd, J = 19, 1.0 Hz), 4.42 (1H, br d, J = 12.5 Hz), 4.80 (1H, br d, J = 12.5 Hz), 7.44 (1H, br d, J = 8.5 Hz), 8.10 (1H, dd, J = 8.5, 2.0 Hz), 8.89 (1H, d, J = 2.0 Hz).\n\n<ê¸ë¦¬ì¤ëí¸ë¦° D><Glionitrine D>\n\nESI-MS: m/z 440 [M+Na]+; ESI-MS: m / z 440 [M + Na] + ;\n\n1H NMR(500 MHz, CDCl3): 3.21(3H, s), 3.48(1H, br dd, J=18.5, 1.0 Hz), 4.02(1H, br dd, J=18.5, 1.0 Hz), 4.12(1H, br d, J=12.5 Hz), 4.40(1H, br d, J= 12.5 Hz), 7.52(1H, br d, J=8.5 Hz), 8.18(1H, dd, J=8.5, 2.0 Hz), 9.18(1H, d, J=2.0Hz). 1 H NMR (500 MHz, CDCl 3 ): 3.21 (3H, s), 3.48 (1H, br dd, J = 18.5, 1.0 Hz), 4.02 (1H, br dd, J = 18.5, 1.0 Hz), 4.12 ( 1H, br d, J = 12.5 Hz), 4.40 (1H, br d, J = 12.5 Hz), 7.52 (1H, br d, J = 8.5 Hz), 8.18 (1H, dd, J = 8.5, 2.0 Hz) , 9.18 (1H, doublet, J = 2.0 Hz).\n\n<< ì¤ììExample 5> Â 5> ê¸ë¦¬ì¤ëí¸ë¦°ìGlynitrin ìì¸í¬ì ëí ì¸í¬ë ì±í¨ê³¼ì ë°í ë¦¬ì ê· ì£¼ Â Cytotoxic Effects on Cancer Cells and Bacterial Strains KMKKMK -001ì ëí í­ê· í¨ê³¼ ì¸¡ì Of antimicrobial effects on -001\n\në³¸ ë°ëª ìë¤ì ê¸ë¦¬ì¤ëí¸ë¦°ì ìì¸í¬ì ëí ì¸í¬ë ì± íê°ë ìíê´ ë´ìì MTT(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltrazdium bromide) ë¶ìë²ì ì´ì©íì¬ ì´ììë ìì¸í¬ì ìì ì¸¡ì íë ë°©ë²ì ìííìë¤. ê¸ë¦¬ì¤ëí¸ë¦°ì ìì¸í¬ë ì±ì American Type Culture Collection(ATCC, Manassas, VA, USA)ë¡ë¶í° ë¶ìë°ì AGS(ìì, ATCC ì¸í¬ì½ë- CRL-1739TM), HepG2(ê°ì, HB-8065TM), HCT116(ëì¥ì, CCL-247TM), A549(íì, CCL-185TM) ë° DU145(ì ë¦½ì ì, HTB-81TM) ìì¸í¬ì£¼ë¥¼ ì¬ì©íì¬ íê°íìë¤. 96-ì° íë ì´í¸(well plate)ì ìì(AGS), ê°ì(HepG2), ëì¥ì(HCT-116), íì(A549) ë° ì ë¦½ì ì(DU-145)ì¸í¬ì£¼ë¥¼ ê°ê° 1 X 104 ì¸í¬ë§í¼ 100 ë§ì´í¬ë¡ë¦¬í°ì© ê°íê³ 37âìì 24ìê° ëì CO2 ë°°ìê¸°ìì ë°°ìíë¤. ì´í ê¸°ì¡´ì ë°°ì§ë¥¼ ì ê±°í í, ê¸ë¦¬ì¤ëí¸ë¦°ê³¼ í¼í©í ìë¡ì´ ë°°ì§ë¡ êµì²´íê³ 37âìì ë°°ìíë¤. 24ìê° í, MTT ì©ì¡ì 10 ë§ì´í¬ë¡ë¦¬í°ì© ë£ì´ 37âìì 1ìê° ë°°ìí í ì´ììë ì¸í¬ ë´ìì íì í¨ìì ìíì¬ íì±ë í¬ë¥´ë§ì¡´ ìì 450nmìì í¡ê´ëë¥¼ ì¸¡ì íìë¤.The present inventors evaluated the cytotoxicity of glynitrin on cancer cells by measuring the amount of living cancer cells using MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphenyltrazdium bromide) assay in vitro. The method was performed. The cancer cytotoxicity of glynitrin was measured by AGS (Stomach Cancer, ATCC Cell Code- CRL-1739 TM ), HepG2 (Liver Cancer, HB-8065 TM ), and HCT116 (Colon Cancer, CCL-247 â¢ ), A549 (lung cancer, CCL-185 â¢ ) and DU145 (prostate cancer, HTB-81 â¢ ) cancer cell lines. In a 96-well plate, 100 micrograms of gastric cancer (AGS), liver cancer (HepG2), colorectal cancer (HCT-116), lung cancer (A549) and prostate cancer (DU-145) cell lines, 1 x 10 4 cells, respectively. Add liters and incubate in CO 2 incubator at 37 Â° C. for 24 hours. After removing the existing medium, replace with fresh medium mixed with glinitrine and incubated at 37 â. After 24 hours, 10 microliters of MTT solution was added and incubated at 37 Â° C. for 1 hour, and the absorbance at 450 nm was measured for the amount of formazone formed by reductase in living cells.\n\nìíê´ ë´ìì 6ê°ì 6 in vitro ìì¸í¬ì£¼ìOn cancer cell lines ëí Â About ê¸ë¦¬ì¤ëí¸ë¦°Glionnitrin A ë° Bì ì¸í¬ë ì± í¨ê³¼Â Cytotoxic Effects of A and B IC50 ê°(mM)IC 50 value (mM) ìì¸í¬ì£¼Cancer cell line ê¸ë¦¬ì¤ëí¸ë¦° AGlionitrine A ê¸ë¦¬ì¤ëí¸ë¦° BGlionitrine B AGSAGS 0.45Â±0.110.45 Â± 0.11 1.25Â±0.21.25 Â± 0.2 DU-145DU-145 0.24Â±0.020.24 Â± 0.02 2.29Â±0.142.29 Â± 0.14 HCT-116HCT-116 0.82Â±0.110.82 Â± 0.11 3.28Â±0.553.28 Â± 0.55 A549A549 0.55Â±0.070.55 Â± 0.07 2.25Â±0.252.25 Â± 0.25 HepG2HepG2 2.28Â±0.32.28 Â± 0.3 >2uM> 2uM MCF-7MCF-7 >2uM> 2uM >2uM> 2uM\n\nìê¸° ê²°ê³¼, í 2ìì ë³´ë ë°ì ê°ì´ ê¸ë¦¬ì¤ëí¸ë¦° A ëë Bë ìê¸° ìì¸í¬ì£¼ë¤ì ëí´ ëì ì¸í¬ë ì± í¨ê³¼ê° ììì ì ì ìë¤.As a result, as shown in Table 2, it can be seen that glynitrin A or B has a high cytotoxic effect on the cancer cell lines.\n\nëí, ë³¸ ë°ëª ìë¤ì ê¸ë¦¬ì¤ëí¸ë¦° A ë° Bì KMK-001 ê· ì£¼ì ëí í­ê· í¨ê³¼ë ëì¤í¬ íì° ì¤íì íµí´ì íì¸ëìë¤. KMK-001ì ì°¨íë ì¤ íì² ë°°ì§ì ëë§í í ê¸ë¦¬ì¤ëí¸ë¦°ì í¡ììí¨ ë©¸ê· ëì¤í¬ë¥¼ ê°ì ë°°ì§ì ì¬ë ¤ëì ë¤ì 25âìì 5ì¼ê° ë°°ìíìë¤. ìì±ëì¡°êµ°ì¼ë¡ ê¸ë¦¬ì¤ëí¸ë¦° ëì ì°í¼ì¤ë¦°ì í¡ììí¨ ë©¸ê· ëì¤í¬ë¥¼ ìê¸°ì ê°ì ì¡°ê±´ì¼ë¡ ë°°ìíìë¤. ìê¸° ê²°ê³¼, ê¸ë¦¬ì¤ëí¸ë¦°ì ì°í¼ì¤ë¦°ê³¼ ì ì¬í í­ê· í¨ê³¼ë¥¼ ëíëì íì¸íìë¤(ë 6 ì°¸ì¡°).In addition, the present inventors have confirmed the antimicrobial effect on the KMK-001 strain of glynitrin A and B through a disk diffusion experiment. KMK-001 was plated on the Chapex dox agar medium, and then the sterile disc absorbed with glinitrine was placed on the same medium and incubated at 25 Â° C. for 5 days. As a positive control, sterile discs in which ampicillin was absorbed instead of glynitrin were cultured under the same conditions. As a result, it was confirmed that glynitrin had an antimicrobial effect similar to ampicillin (see FIG. 6).\n\nëí, ë³¸ ë°ëª ìë¤ì ê¸ë¦¬ì¤ëí¸ë¦° Aì Bì í­ê· í¨ê³¼ë¥¼ American Type Culture Collection(ATCC, Manassas, VA, USA)ë¡ë¶í° ë¶ìë°ì ë§ì´í¬ë¡ì½ì¿ ì¤ ë¡ì´í ì°ì¤(Micrococcus leuteus) IFC 12708, ë°ì¤ë¬ì¤ ìë¸í¸ë¬ì¤(Bacillus subtilis) ATCC 6633, íë¡í ì°ì¤ ë¶ê°ë¦¬ì¤(Proteus vulgaris) ATCC 3851, ì´ëª¨ë¬ë¼ í°í¼ë¬´ë¦¬ì(Salmonella typhimurium) ATCC 1 4028 ë° 3ì¢ ì ë©í°ì¤ë¦° ë´ì± í©ìí¬ëìêµ¬ê· (MRSA)ì¸ ì¤íí¼ë¡ì½ì¿ ì¤ ìì°ë ì°ì¤(Staphylococcus aureus) ATCC 43300, ì¤íí¼ë¡ì½ì¿ ì¤ ìì°ë ì°ì¤(S. aureus) ATCC 700787 ë° ì¤íí¼ë¡ì½ì¿ ì¤ ìì°ë ì°ì¤(S. aureus) ATCC 700788ì ëíì¬ íê°íìë¤. ê¸ë¦¬ì¤ëí¸ë¦° Bë ëª¨ë ìíêµ°ìì í­ê· ìì©ì´ ìë ë°ë©´ì, ê¸ë¦¬ì¤ëí¸ë¦° Aë 4ì¢ ì ë¹ë´ì±ê· ìì 0.78-3.13 ug/mLì ìµììµì ëë(MIC)ë¡ ìì±ëì¡°êµ°ì¼ë¡ ì¬ì©í ìí¼ì¤ë¦°(Ampicillin)ê³¼ ì ì¬í ê°ë ¥í í­ê· ìì©ì ëíë´ìë¤. í¹í ê¸ë¦¬ì¤ëí¸ë¦° Aë 3ì¢ ì MRSAê· ë¤ìë 0.78 ug/mLì MIC ëëë¡ ìì±ëì¡°êµ°ì¼ë¡ ì¬ì©í ìí¼ì¤ë¦°(Ampicillin)ì í­ê· ìì©ë³´ë¤ 15ë°° ì´ìì ê°ë ¥í ë©í°ì¤ë¦° ë´ì± í©ì í¬ëìêµ¬ê· ì ëí í­ê· ìì©ì ëíë´ìë¤(í 3 ì°¸ì¡°). ìê¸° 7ì¢ ì ë°í ë¦¬ì ê· ì£¼ë¤ì ëí ê¸ë¦¬ì¤ëí¸ë¦°ì ìµììµì ëëë¥¼ ì¸¡ì íê¸° ìíì¬ ìê¸° 7ì¢ ì ë°í ë¦¬ìë¥¼ íì¤ë°°ì§(Standard Methods Broth)(Difco)ìì 24ìê° ëì ë°°ìíìë¤. ì´í ê¸°ì¡´ì ë°°ì§ë¥¼ ì ê±°í í ê°ê°ì ê· ì£¼ë¥¼ 105ì ì½ë¡ë íì± ë¨ì(cfu)/mLë¥¼ í¨ì í ë°°ì§ë¥¼ 100 ë§ì´í¬ë¡ë¦¬í°ì© ì·¨íì¬ 96-ì° íë ì´í¸ì ê°íê³ , ê¸ë¦¬ì¤ëí¸ë¦°ì ëëë³ë¡ í¬ìíì¬ ê°í í 37âìì 24ìê° ë°°ìíìë¤. 24ìê° í 600 nmìì ê´íë°ë(Optical density)ë¥¼ ì¸¡ì íìë¤. In addition, the present inventors articles are pleased to the antimicrobial effect of the trim A and B American Type Culture Collection (ATCC, Manassas, VA, USA) microcode kusu Roy Proteus (Micrococcus received from the pre-sale leuteus) IFC 12708, Bacillus sub-blocks bus (Bacillus subtilis) ATCC 6633, Proteus vulgaris (Proteus vulgaris) ATCC 3851, Salmonella typhimurium bunch moth (Salmonella typhimurium) ATCC 1 4028 and the methicillin-resistant Staphylococcus aureus (MRSA) star fatigue of the three nose kusu aureus (Staphylococcus aureus ) ATCC 43300, Staphylococcus aureus ( S. aureus ) It was evaluated against ATCC 700787, and co-stars fatigue Syracuse aureus (S. aureus) ATCC 700788. Glynitrin B had no antimicrobial activity in all test groups, whereas glynitrin A was used as a positive control with Ampicillin, which was used as a positive control at a minimum inhibitory concentration (MIC) of 0.78-3.13 ug / mL in four non-resistant bacteria. Similar potent antimicrobial activity was shown. In particular, glynitrin A exhibited 15 times more potent antimicrobial activity against methicillin-resistant Staphylococcus aureus than the antimicrobial activity of Ampicillin, which was used as a positive control at a concentration of 0.78 ug / mL for three MRSA bacteria ( See Table 3). The seven bacteria were incubated for 24 hours in Standard Methods Broth (Difco) to determine the minimum inhibitory concentration of glynitrin for the seven bacterial strains. Then, after removing the existing medium, each strain was added to the 96-well plate by taking 100 microliters of a medium containing 10 5 colony forming units (cfu) / mL, and diluted with the concentration of glinonitrile 37 Incubated for 24 hours at â. Optical density was measured at 600 nm after 24 hours.\n\nëí, ë³¸ ë°ëª ìë¤ì American Type Culture Collection(ATCC, Manassas, VA, USA)ë¡ë¶í° ë¶ìë°ì ìì¤í¼ì§ë¬ì¤ í¸ë¯¸ê°í¬ì¤(Aspergillus fumigatus) HIC 6094ì T.ë£¨ë¸ë¼(Trichophyton rubrum) IFO 9185ì ëí ê¸ë¦¬ì¤ëí¸ë¦° Aì Bì í­ì§ê· ìì©ì íê°íìë¤. ìê¸°í í­ê· ìì©ê³¼ ì ì¬íê² ê¸ë¦¬ì¤ëí¸ë¦° Bë í­ì§ê· ìì©ì´ ìë ë°ë©´, ê¸ë¦¬ì¤ëí¸ë¦° Aë 12.5 ug/mLì ìµììµì ëë(MIC)ë¥¼ ëíë´ìë¤(í 3 ì°¸ì¡°). ìê¸° 2ì¢ ì ì§ê· ë¤ì ëí ê¸ë¦¬ì¤ëí¸ë¦°ì ìµììµì ëëë¥¼ ì¸¡ì íê¸° ìíì¬, ìê¸° 2ì¢ ì ì§ê· ì í¬ìë¥¼ ê°ê° 1 ë°ë¦¬ë¦¬í° ë¹ 105ì¹ì í¬ììê° ëëë¡ ë©¸ê· ì¦ë¥ìë¡ íííê³ ì¬ë¶ë¡ í´ë£¨ì½ì¦(Sabouraud glucose) ì¡ì²´ë°°ì§(Difco)ë¥¼ ì´ì©íì¬ ë°ë¦¬ë¦¬í° ë¹ 103ì ì¸í¬ìê° ëëë¡ ë§ë¤ìë¤. ì´í 96-ì° íë ì´í¸(well plate)ì 102ì ì¸í¬ ìë§í¼ 100 ë§ì´í¬ë¡ë¦¬í°ì© ê°íê³ ê¸ë¦¬ì¤ëí¸ë¦°ì ëëë³ë¡ ê°í í, 48ìê° ëì 28âìì ë°°ìíìë¤. ê³°í¡ì´ì ì±ì¥ì´ ê´ì°°ëì§ ìë ê¸ë¦¬ì¤ëí¸ë¦°ì ëëë¥¼ ìµììµì ëëë¡ íìë¤.In addition, the inventors of the present invention, Aspergillus Pumigatus ( Aspergillus pumigatus) received from the American Type Culture Collection (ATCC, Manassas, VA, USA) fumigatus ) HIC 6094 and T. lubrum ( Trichophyton rubrum ) The antifungal action of glynitrin A and B on IFO 9185 was evaluated. Similar to the antimicrobial action described above, glynitrin B had no antifungal action, while glynitrin A showed a minimum inhibitory concentration (MIC) of 12.5 ug / mL (see Table 3). In order to determine the minimum inhibitory concentration of glynitrin for the two fungi, the spores of the two fungi were each suspended in sterile distilled water to give 10 5 rounds of spores per milliliter, respectively. ) Liquid medium (Difco) was used to give a cell count of 10 3 per milliliter. Thereafter, 100 microliters of 10 2 cells were added to the 96-well plate, and glynitrin was added by concentration, and then cultured at 28 Â° C. for 48 hours. The concentration of glynitrin for which no fungus growth was observed was taken as the minimum inhibitory concentration.\n\nìíê´ ë´ìì 9ì¢ ì ì í´ê· ì ëí In vitro, 9 kinds of harmful bacteria ê¸ë¦¬ì¤ëí¸ë¦°Glionnitrin A ë° Bì í­ê· ìì©Â Antimicrobial Activity of A and B ì í´ê· Â Â Harmful bacteria ê¸ë¦¬ì¤ëí¸ë¦° A MIC(ug/mL)Glionitrin A MIC (ug / mL) ê¸ë¦¬ì¤ëí¸ë¦° B MIC(ug/mL)Glionitrin B MIC (ug / mL) í­ê· ëì¡°êµ° ìí¼ì¤ë¦° MIC(ug/mL)Antimicrobial Control Ampicillin MIC (ug / mL) í­ì§ê· ëì¡°êµ° ìí¬í ë¦¬ì B MIC(ug/mL)Antifungal control amphotericin B MIC (ug / mL) Micrococus leuteus IFC 12708[G(+)] Micrococus leuteus IFC 12708 [G (+)] 0.780.78 >100> 100 0.780.78 -- Bacillus subtilis ATCC 6633[G(+)] Bacillus subtilis ATCC 6633 [G (+)] 6.256.25 >100> 100 3.133.13 -- Proteus vulgaris ATCC 3851[G(-)] Proteus vulgaris ATCC 3851 [G (-)] 3.133.13 >50> 50 1.561.56 -- Salmonella typhimurium ATCC 14028[G(-)] Salmonella typhimurium ATCC 14028 [G (-)] 3.133.13 >50> 50 12.512.5 -- Staphylococcu aureus ATCC 4330(MRSA) Staphylococcu aureus ATCC 4330 (MRSA) 0.780.78 >50> 50 12.512.5 -- S. aureus ATCC 700787(MRSA) S. aureus ATCC 700787 (MRSA) 0.780.78 >50> 50 12.512.5 -- S. aureus ATCC 700788(MRSA) S. aureus ATCC 700788 (MRSA) 0.780.78 >50> 50 25.025.0 -- Aspergillus fumigatus HIC 6094 Aspergillus fumigatus HIC 6094 12.512.5 >50> 50 -- 1.561.56 Trichophyton rubrum IFO 9185 Trichophyton rubrum IFO 9185 12.512.5 >50> 50 -- 1.561.56\n\nìê¸° ê²°ê³¼, í 3ìì ë³´ë ë°ì ê°ì´ ê¸ë¦¬ì¤ëí¸ë¦° Aë ìê¸° ì í´ê· ë¤ì ëí´ ëì í­ê· í¨ê³¼ê° ììì ì ì ìë¤.As a result, as shown in Table 3, it can be seen that glinotrin A has a high antibacterial effect against the harmful bacteria.\n\níê¸°ì ë³¸ ë°ëª ì ì¡°ì±ë¬¼ì ìí ì ì ìë¥¼ ììíë¤.Examples of preparations for the compositions of the present invention are illustrated below.\n\n<< ì ì ìFormulation example 1> Â 1> ì°ì ìPowder ì ì¡°Â Produce\n\nííì 3 ëë ííì 4ì íí©ë¬¼ 20 mg20 mg of compound of Formula 3 or Formula 4\n\nì ë¹ 100 mgLactose 100 mg\n\níí¬ 10 mgTalc 10 mg\n\nìê¸°ì ì±ë¶ë¤ì í¼í©íê³ ê¸°ë°í¬ì ì¶©ì§íì¬ ì°ì ë¥¼ ì ì¡°íë¤.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.\n\n<ì ì ì 2> ì ì ì ì ì¡° Formulation Example 2 Preparation of Tablet\n\nííì 3 ëë ííì 4ì íí©ë¬¼ 10 mg10 mg of a compound of Formula 3 or Formula 4\n\nì¥ììì ë¶ 100 mgCorn starch 100 mg\n\nì ë¹ 100 mgLactose 100 mg\n\nì¤í ìë¦°ì° ë§ê·¸ë¤ì 2 mg2 mg magnesium stearate\n\nìê¸°ì ì±ë¶ë¤ì í¼í©í í íµìì ì ì ì ì ì¡°ë°©ë²ì ë°ë¼ì íì íì¬ ì ì ë¥¼ ì ì¡°íë¤.After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.\n\n<< ì ì ìFormulation example 3> ìº¡ìì ì ì ì¡° Â 3> Preparation of capsule\n\nííì 3 ëë ííì 4ì íí©ë¬¼ 10 mg10 mg of a compound of Formula 3 or Formula 4\n\nê²°ì ì± ì ë£°ë¡ì¤ì¤ 3 mg3 mg of crystalline cellulose\n\në½í ì¤ì¤ 14.8 mgLactose 14.8 mg\n\në§ê·¸ë¤ì ì¤í ìë ì´í¸ 0.2 mgMagnesium Stearate 0.2 mg\n\níµìì ìº¡ìì  ì ì¡°ë°©ë²ì ë°ë¼ ìê¸°ì ì±ë¶ì í¼í©íê³ ì ¤ë¼í´ ìº¡ìì ì¶©ì íì¬ ìº¡ìì ë¥¼ ì ì¡°íë¤.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.\n\n<< ì ì ìFormulation example 4> ì£¼ì¬ì ì ì ì¡°Â 4> Preparation of Injection\n\nííì 3 ëë ííì 4ì íí©ë¬¼ 10 mg10 mg of a compound of Formula 3 or Formula 4\n\në§ëí¨ 180 mgMannitol 180 mg\n\nì£¼ì¬ì© ë©¸ê· ì¦ë¥ì 2974 mgSterile distilled water for injection 2974 mg\n\nNa2HPO4 ,12H2O 26 mgNa 2 HPO 4 , 12H 2 O 26 mg\n\níµìì ì£¼ì¬ì ì ì ì¡°ë°©ë²ì ë°ë¼ 1 ì°íë¹(2ã) ìê¸°ì ì±ë¶ í¨ëì¼ë¡ ì ì¡°íë¤.According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).\n\n<< ì ì ìFormulation example 5> Â 5> ì¡ì ìLiquid ì ì¡°Â Produce\n\nííì 3 ëë ííì 4ì íí©ë¬¼ 20 mg20 mg of compound of Formula 3 or Formula 4\n\nì´ì±íë¹ 10 g10 g of isomerized sugar\n\në§ëí¨ 5 g5 g of mannitol\n\nì ì ì ì ëPurified water"
    }
}